---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Product information and disease description. Covers Product description and Place of product in therapy. 361 evidence topics quoted from 144 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: regulatory history and status

- Current status: under FDA review. Apnimed submitted a New Drug Application (NDA) for Oxnimbi (AD109) through the section 505(b)(2) pathway in April 2026; the FDA accepted it for review in July 2026 and assigned a PDUFA goal date of February 28, 2027. The 10-Q states that the review cycle is targeted at 10 months from the April 2026 submission. No launch date has been stated.
- Designations: Fast Track designation for the treatment of OSA in May 2022.
- Proprietary name: Oxnimbi is a proposed name. The prospectus states that the FDA conditionally approved it in May 2025, reconfirmed it in June 2026, and that it is pending approval of the NDA; the third quarter 2026 release states that it remains subject to final FDA review and may change.
- Combination product requirement: as a fixed-dose combination, the product generally requires the sponsor to demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.
- FDA questions: at the pre-NDA meeting, the FDA gave feedback on the “clinical meaningfulness of certain endpoint results”, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. Apnimed states that it responded in the NDA. The third quarter 2026 Form 10-Q states that the FDA, in its acceptance letter and later communications, has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas; its risk factors name the adequacy of stability data and the manufacturing process.
- Development completed: 13 phase 1, 2, and 3 trials, including two registrational phase 3 trials (LunAIRo in the United States and SynAIRgy in the United States and Canada).
- Earlier timing statements, now superseded: the May 2025 and July 2025 topline releases planned an NDA submission by early 2026; the March 2026 release expected submission in the second quarter of 2026; the April 2026 debt financing release expected it later that quarter; the May 2026 SynAIRgy publication release expected a PDUFA target action date in the first quarter of 2027, subject to FDA acceptance. The July 2026 acceptance, with a goal date of February 28, 2027, replaced these statements.

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and); [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109); [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm); [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109); [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty); [Apnimed SASS monetization release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-strategic-monetization-shionogi-apnimed-sleep); [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/); [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted April 2026 and accepted July 2026, with a PDUFA goal date of February 2027

> “Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026, which was accepted for review by the FDA in July 2026.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Apnimed’s NDA for AD109 is under review by the FDA and was assigned a PDUFA goal date of February 28, 2027.”
> “The FDA has assigned a PDUFA goal date of February 28, 2027.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### NDA acceptance and PDUFA target action date, July 2026

> “The FDA assigned a PDUFA target action date of February 28, 2027”
> “Apnimed’s NDA for AD109 was assigned a PDUFA target action date of February 28, 2027.”

Source: [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109)

<a id="topic-2.1.1-5"></a>

##### Review timeline: 10-month review from submission

> “The FDA review cycle is targeted to be 10 months from our NDA submission in April 2026”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-6"></a>

##### Regulatory pathway: section 505(b)(2) NDA

> “We submitted a NDA to seek FDA approval for Oxnimbi for OSA through the Section 505(b)(2) regulatory pathway.”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-7"></a>

##### Fixed-dose combination rule

> “Oxnimbi is a fixed-dose combination drug product. The development of combination therapies may be more complex than the development of single agent therapies and generally requires that sponsors demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-8"></a>

##### Fast Track designation, May 2022

> “In May 2022, we received Fast Track designation for Oxnimbi for the treatment of OSA”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-9"></a>

##### FDA pre-NDA feedback on the clinical meaningfulness of endpoint results

> “In connection with the FDA’s review of our top-line Phase 3 data, at the pre-NDA meeting, the FDA provided feedback about the clinical meaningfulness of certain endpoint results, including the primary endpoint and the limitations of the patient-reported outcomes (PROs). The FDA indicated that additional analyses and justification may be needed to support that the data demonstrates a clinically meaningful benefit for the treatment of OSA. We submitted information in response to this feedback in our NDA submission and plan to continue to address it and related requests as part of the FDA review process.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-10"></a>

##### FDA questions raised in the acceptance letter and during review

> “In its acceptance letter and in any later communications during its review, the FDA has raised and may continue to raise questions or concerns regarding the adequacy of our NDA to support approval and has requested and may further request additional information, data or analyses to augment its review of the nonclinical, clinical or CMC areas of our application, which could require that we submit amendments to our NDA.”
> “the adequacy of our stability data and manufacturing process to support approval and commercial launch;”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-11"></a>

##### Clinical development completed: two phase 3 trials and 13 trials overall

> “We have conducted 13 Phase 1, 2 and 3 clinical trials that inform various aspects of the Oxnimbi program and have amassed clinical response and tolerability data for Oxnimbi across multiple completed clinical trials in OSA.”
> “LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada. All previous trials of Oxnimbi were conducted in the United States.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-12"></a>

##### PDUFA date expectation, May 2026, superseded in July 2026

> “Apnimed has submitted its NDA for AD109 to the FDA. Based on FDA’s prior feedback, Apnimed expects a potential Prescription Drug User Fee Act (PDUFA) target action date in the first quarter of 2027, subject to FDA acceptance of the NDA for review.”

Source: [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109)

<a id="topic-2.1.1-13"></a>

##### NDA submission timing, April 2026, superseded in April 2026

> “Apnimed previously reported positive results from the pivotal SynAIRgy and LunAIRo Phase 3 trials for AD109, which will support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, expected later this quarter.”

Source: [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty)

<a id="topic-2.1.1-14"></a>

##### NDA submission timing, March 2026, superseded in April 2026

> “Transaction strengthens Apnimed’s balance sheet as the Company separately prepares to submit its NDA for AD109 in Obstructive Sleep Apnea, expected in the second quarter of 2026”

Source: [Apnimed SASS monetization release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-strategic-monetization-shionogi-apnimed-sleep)

<a id="topic-2.1.1-15"></a>

##### NDA submission timing, July 2025, superseded in March 2026

> “Apnimed plans to submit a New Drug Application for AD109 to the U.S. Food and Drug Administration (FDA) by early 2026”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-2.1.1-16"></a>

##### NDA submission timing, May 2025, superseded in March 2026

> “Apnimed plans to submit a New Drug Application (NDA) for AD109 to the U.S. Food and Drug Administration (FDA) by early 2026 for regulatory review.”

Source: [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Apnimed

> “AD109 is Apnimed’s investigational drug candidate, with a proposed proprietary name Oxnimbi.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

> “Retain worldwide rights”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.1.2.1-2"></a>

###### Established name and proposed proprietary name

> “Our clinical product candidate, AD109 with a proposed proprietary name Oxnimbi”
> “(aroxybutynin and atomoxetine) tablets, for oral use”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

> “This brand name was conditionally approved by the FDA in May 2025, which was reconfirmed in June 2026, and is pending approval of the NDA in its totality.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “The proposed name remains subject to final FDA review and acceptance and may change.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class: anti-apneic neuromuscular modulator combining an antimuscarinic and a norepinephrine reuptake inhibitor

> “is an investigational, fixed-dose anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

> “It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.1-4"></a>

###### Aroxybutynin: the R-enantiomer of oxybutynin, not previously approved

> “Aroxybutynin (also known as R-oxybutynin) is a novel drug that, to our knowledge, has not previously been marketed or approved by the FDA or any other regulatory agency, for any indication.”
> “Oxybutynin is composed of an equal mixture of aroxybutynin and S-oxybutynin, i.e., it is a racemic mixture.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Strengths filed in the NDA: aroxybutynin and atomoxetine base with hydrochloride equivalents

> “In July 2026, the FDA accepted for review the NDA filing of Oxnimbi 2.3mg of aroxybutynin and 37.5mg atomoxetine (equivalent to 2.5mg of aroxybutynin hydrochloride and 42.85mg of atomoxetine hydrochloride) or 2.3mg aroxybutynin and 75mg atomoxetine (equivalent to 2.5mg of aroxybutynin hydrochloride and 85.7mg of atomoxetine hydrochloride) for the treatment of adults with OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.2-2"></a>

###### Dosage form: fixed-dose oral tablet taken once nightly

> “It is a fixed-dose  oral tablet anti-apneic neuromuscular modulator co-formulated with our novel anti-muscarinic aroxybutynin (2.3mg) combined with the NRI atomoxetine (75mg) equivalent to 2.5mg of aroxybutynin hydrochloride and 85.7mg of atomoxetine hydrochloride.”
> “Oxnimbi is formulated into a small tablet that is taken once nightly, just prior to bedtime.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.2-3"></a>

###### Strength notation in publications: aroxybutynin 2.5 mg/atomoxetine 75 mg

> “AD109 (investigational fixed-dose oral combination of aroxybutynin 2.5 mg/atomoxetine 75 mg) is designed to target neuromuscular dysfunction in OSA.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.2-4"></a>

###### Phase 3 investigational product supply: run-in blister pack and target-dose bottle

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication under FDA review: adults with obstructive sleep apnea

> “filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea”

Source: [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109)

<a id="topic-2.1.2.5-2"></a>

###### Intended disease severity range: mild, moderate, and severe

> “We are developing Oxnimbi with the intent for broad utilization across the spectrum of disease severity (mild, moderate and severe).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.5-3"></a>

###### Phase 3 population: adults intolerant to or refusing PAP therapy

> “SynAIRgy enrolled adults with mild-to-severe OSA who were intolerant to or refused PAP therapy into a randomized, double-blind, placebo-controlled, 26-week parallel-arm trial of AD109 vs placebo across 69 centers.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “All participants must be PAP intolerant or have refused PAP to enroll.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Combination: company description of the target and the two components

> “Oxnimbi is a combination of aroxybutynin and atomoxetine designed to target the neuromuscular defect of OSA and improve upper airway muscle activity during sleep.”
> “Aroxybutynin is a type of anticholinergic agent that blocks the activity of the muscarinic acetylcholine receptor”
> “The selection of atomoxetine is to promote adrenergic tone leading to muscle activation.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Combination: noradrenergic excitation and antimuscarinic disinhibition of the hypoglossal motor nucleus

> “AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.”
> “Atomoxetine, a selective norepinephrine reuptake inhibitor, was expected to increase synaptic norepinephrine and enhance central excitatory drive to upper airway motor neurons, thereby improving dilator muscle tone. Aroxybutynin, a selective antimuscarinic agent, was hypothesized to reduce muscarinic inhibition of HMN activity (Figures 1 and 2). Together, this dual mechanism was designed to stabilize upper airway muscle activation across NREM and REM sleep and mitigate sleep-related relaxation of the airway.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.1-3"></a>

###### Combination: proposed mechanism by which aroxybutynin offsets the wake-promoting effect of atomoxetine, not yet shown in animal models

> “Thus, when combined, a significant potential benefit of aroxybutynin and atomoxetine is the overall stabilization of sleep through the mitigation of the wake-promoting activity caused by atomoxetine.”
> “Since atomoxetine administration promotes wakefulness alongside an increase in cortical acetylcholine levels, we have hypothesized that the attenuation of this wake-promoting effect by co-administration of aroxybutynin is due to the blockade of atomoxetine-evoked cholinergic stimulation of the cortex. In this scenario, aroxybutynin would block atomoxetine-mediated activation of a critical arousing pathway while importantly preserving the α1-receptor-dependent activation of upper airway motor pathways. Although this theoretical mechanism has not yet been proven in animal models, we believe it represents a plausible explanation for the unique effects observed when combining these two compounds on OSA severity, upper airway muscle activity and sleep continuity.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Aroxybutynin: the R-enantiomer of racemic oxybutynin

> “Aroxybutynin (also known as R-oxybutynin) is a novel drug that, to our knowledge, has not previously been marketed or approved by the FDA or any other regulatory agency, for any indication.”
> “Oxybutynin is composed of an equal mixture of aroxybutynin and S-oxybutynin, i.e., it is a racemic mixture.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 refined the original combination by substituting oxybutynin with aroxybutynin, the R-enantiomer that mediates most of oxybutynin’s antimuscarinic actions.”
> “Concentrating the pharmacologic activity in a single active stereoisomer allows for equivalent effects on the upper airway at a lower total dose, with the potential for fewer off-target effects and better overall tolerability.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.1-5"></a>

###### Oxybutynin label: muscarinic antagonism residing predominantly in the R-isomer

> “Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle.”
> “Antimuscarinic activity resides predominantly in the R-isomer.”
> “A metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin in in vitro studies.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.6.1-6"></a>

###### Atomoxetine label: selective inhibition of the presynaptic norepinephrine transporter

> “Atomoxetine is a selective norepinephrine reuptake inhibitor.”
> “The precise mechanism by which STRATTERA produces its therapeutic effects in ADHD is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.”
> “4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Atomoxetine plus racemic oxybutynin, single night: genioglossus responsiveness and AHI (hypopneas with 3% desaturation or arousal)

> “ato–oxy lowered AHI by 63% (34–86%), from 28.5 (10.9–51.6) events/h to 7.5 (2.4–18.6) events/h (P < 0.001).”
> “Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1–4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato–oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately.”
> “Hypopneas were defined as reduction in flow of 30% or more from baseline, lasting at least 10 seconds, and were associated with an arousal from sleep or an oxyhemoglobin desaturation 3% or greater.”

Source: [Taranto-Montemurro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6519859/)

<a id="topic-2.1.2.6.2-2"></a>

###### Atomoxetine plus racemic oxybutynin: effects on endotypic traits

> “Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by –9 [–14 to –3]% (P = .022) and LG1 by –11 [–22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation.”
> “Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.”

Source: [Taranto-Montemurro et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7268440/)

<a id="topic-2.1.2.6.2-3"></a>

###### Atomoxetine alone versus atomoxetine plus racemic oxybutynin (AD036), home sleep studies (hypopneas with 4% desaturation)

> “The apnea–hypopnea index (AHI) from a median (interquartile range) of 14.2 (5.4 to 22.3) events/h on placebo to 6.2 (2.8 to 13.6) with AD036 and 4.8 (1.4 to 11.6) with atomoxetine alone (p < .0001).”
> “AD036, but not atomoxetine alone, reduced the respiratory arousal index and improved ventilation at the respiratory arousal threshold (greater Vactive). There was a trend for total sleep time to be decreased more with atomoxetine alone than with AD036.”
> “Atomoxetine may account for the majority of improvement in OSA severity, while the addition of oxybutynin may mitigate the disruptive effect of atomoxetine on sleep and further improve ventilation.”
> “The 4% oxygen desaturation criterion was used for scoring of hypopneas and subsequent calculation of the AHI, and for calculation of the oxygen desaturation index (ODI).”

Source: [Schweitzer et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9098382/)

<a id="topic-2.1.2.6.2-4"></a>

###### Choice of antimuscarinic: atomoxetine with solifenacin or biperiden (AASM scoring)

> “Neither drug combination altered the apnea/hypopnea index versus placebo (P = 0.63).”
> “Atomoxetine + biperiden hydrochloride reduces perceived sleepiness, and atomoxetine + solifenacin modestly improves upper airway function in people with OSA but to a lesser extent versus recently published atomoxetine + oxybutynin (broad M-subtype receptor selectivity) findings.”
> “All overnight in-laboratory sleep studies (polysomnography) were performed according to American Academy of Sleep Medicine guidelines.”

Source: [Aishah et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8424567/)

<a id="topic-2.1.2.6.2-5"></a>

###### Contribution of the antimuscarinic component to upper airway activity and sleep consolidation

> “However, it has become clear, after multiple similar findings, that the SNRIs (atomoxetine or reboxetine) have the most important stimulatory action on the pharyngeal dilator muscles, while the antimuscarinic component has a smaller such effect.”
> “A second important contribution of the anticholinergic agent in the ato-oxy combination was discovered to be the mitigation of the wake-promoting effects caused by the SNRIs.”

Source: [Taranto-Montemurro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12713960/)

> “Oxybutynin was also found to attenuate a reduction in arousal threshold observed with atomoxetine monotherapy, raising the possibility that blocking muscarinic signaling blunts the behavioral/arousal expression of noradrenergic drive48 allowing for HMN activations while maintaining sleep.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.2-6"></a>

###### AD109 versus atomoxetine alone over 4 weeks: respiratory parameters and total sleep time (MARIPOSA)

> “AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.”
> “Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.6.2-7"></a>

###### AD109 dose response after a single night, APC-004 (hypoxic burden and AHI with 4% desaturation)

> “The primary endpoint was the reduction of HB (calculated based on AHI with four percent desaturation) and the reduction of AHI (calculated based on four percent desaturations) was a key secondary endpoint.”
> “Standard dose AD109 significantly reduced HB by 84% (p<0.0001) and AHI by 59% (p<0.0001) relative to placebo. Low dose also significantly reduced HB by 47% (p=0.0048) and AHI by 41% (p<0.05) vs placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.2-8"></a>

###### Apnea index and hypopnea index (4% desaturation criterion) in the phase 3 trials, on-treatment estimand: company exploratory analysis

> “At week 26 in SynAIRgy, AD109 was associated with a 77.2% mean reduction from baseline in the apnea index among patients who remained on treatment (vs 20.2% on placebo), compared with a smaller mean relative reduction of approximately 45.3% in the hypopnea index (vs 12.4% on placebo). Similarly, in LunAIRo, the mean relative reduction of apnea index was 67.1% (vs 2.8% reduction on placebo), while the mean hypopnea index saw a 37.8% reduction (vs 3.1% on placebo). We believe this pattern raises the possibility that AD109 converts some complete obstructive apneas into partial obstructions (hypopneas).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.2-9"></a>

###### REM sleep and body mass index changes in the phase 3 trials

> “In the SynAIRgy clinical trial, changes in BMI at week 26 were negligible across treatment groups; median (interquartile range) change was −0.1 (−1.1 to 0.6) with AD109 and 0.1 (−0.4 to 0.9) with placebo. Change in BMI in LunAIRo at 51 weeks was also small: median (IQR) change was -0.2 (-1.4 to 0.8) with AD109 and -0.1 (-0.9 to 0.7) with placebo. Although AD109 was associated with small reductions in weight and proportion of REM sleep, our adjusted analyses found that these changes had minimal influence on the improvement of AHI observed (Figure 33), supporting that the proposed mechanism of action of AD109 is via improvement in sleep-related neuromuscular dysfunction.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 was associated with a reduction in REM sleep, consistent with the established effects of noradrenergic, serotonergic, and tryciclic antidepressant agents. The clinical significance of pharmacologically driven REM reduction remains uncertain, and existing evidence suggests that it is not associated with impairments in cognitive performance or vigilance.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.2-10"></a>

###### Atomoxetine label: cardiac electrophysiology

> “No large changes in QTc interval (i.e., increases >60 msec from baseline, absolute QTc >480 msec) were observed in the study. However, small changes in QTc interval cannot be excluded from this study, because the study failed to demonstrate assay sensitivity. There was a slight increase in QTc interval with increased atomoxetine concentration.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.2-11"></a>

###### Oxybutynin label: pharmacodynamic effects on the bladder

> “In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

Additional sources: [Gell et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41932835/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Phase 1 bridging study: aroxybutynin 2.3 mg versus racemic oxybutynin 5 mg (APC-001)

> “The trial was a single dose two-way crossover trial in 24 subjects comparing 2.3mg aroxybutynin to 5mg oxybutynin. The trial found that the drug levels of aroxybutynin were consistent with levels seen with racemic oxybutynin. The trial served as a pharmacokinetic bridging study to oxybutynin as a reference listed drug for aroxybutynin.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.3-2"></a>

###### Phase 1: components given alone and in combination, and time to maximum concentration (APC-001 and APC-002)

> “The Phase 1 trials overall established that drug levels of aroxybutynin (APC-001) and atomoxetine (APC-002) were not different whether administered alone or in combination. Both aroxybutynin and atomoxetine were absorbed rapidly with maximum concentrations being observed in one to four hours, which is considered appropriate for a combination therapeutic administered at bedtime and acting during the night.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.3-3"></a>

###### Metabolic pathways of the two components

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.6.3-4"></a>

###### Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type

| Parameter | Other CYP2D6 metabolizer types | CYP2D6 poor metabolizers |
| --- | --- | --- |
| Accumulation | “1.1-fold” | “3.3-fold” |
| Absolute bioavailability | “63%” | “94%” |
| Median time to maximum concentration | “1 hour” | “2.5 hour” |
| Atomoxetine half-life | “5.2 hours” | “21.6 hours” |
| Atomoxetine apparent oral clearance | “0.35 L/hr/kg” | “0.03 L/hr/kg” |
| Primary metabolic pathways | “CYP2D6” | “Other CYP enzymes” |

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Atomoxetine label: food effect, distribution, excretion, and exposure in CYP2D6 poor metabolizers

> “AUC: Unchanged; Cmax: Decreased 37%; Tmax: Delayed 3 hours”
> “Protein Binding 98%”
> “Less than 3% as unchanged drug”
> “Atomoxetine AUC was approximately 10-fold higher and atomoxetine Css, max was approximately 5-fold higher in CYP2D6 poor metabolizers compared to other CYP2D6 metabolizer types”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.3-6"></a>

###### Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose

| Parameter | R-oxybutynin | S-oxybutynin |
| --- | --- | --- |
| Cmax (ng/mL), mean (SD) | “1.0 (0.6)” | “1.8 (1.0)” |
| Tmax (h), mean (SD) | “12.7 (5.4)” | “11.8 (5.3)” |
| Half-life (h), mean (SD) | “13.2 (6.2)” | “12.4 (6.1)” |
| AUCinf (ng•h/mL), mean (SD) | “21.3 (12.2)” | “39.5 (21.2)” |

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.6.3-7"></a>

###### Oxybutynin label: distribution, metabolism, and excretion

> “Both enantiomers of oxybutynin are highly bound (>99%) to plasma proteins.”
> “Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active.”
> “Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.”
> “The rate and extent of absorption and metabolism of oxybutynin are similar under fed and fasted conditions.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information for AD109

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Phase 3 trials: most common adverse events and serious adverse events (company statement)

> “Across both Phase 3 studies, no SAEs or deaths were reported as related to AD109. Most AEs were reported as mild in severity, and the common AEs were consistent with previous trials of AD109. The tolerability profile was consistent with the individual components of the combination. In our Phase 3 clinical trials, dry mouth, insomnia, and nausea were the most common treatment-related AEs (Figure 29; Figure 30).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-3"></a>

###### Pooled phase 3 analysis: treatment-emergent adverse events

> “TEAEs were predominantly mild, with ≥1 TEAE reported by 500 (76.6%) participants on AD109 and 370 (57.3%) on PBO. The most common TEAEs were dry mouth, insomnia, nausea, urinary hesitation, somnolence, and constipation. No AD109-related serious TEAEs were identified.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-2.1.2.7.1-4"></a>

###### SynAIRgy: treatment-emergent adverse events in the safety analysis set

| Measure | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
| --- | --- | --- |
| Any TEAE | “230 (70.8)” | “149 (46.7)” |
| Any treatment-related TEAE | “190 (58.5)” | “75 (23.5)” |
| Any severe TEAE | “15 (4.6)” | “10 (3.1)” |
| Any TEAE leading to treatment discontinuation | “69 (21.2)” | “10 (3.1)” |
| Dry mouth | “115 (35.4)” | “29 (9.1)” |
| Insomnia (initial insomnia, insomnia, and middle insomnia) | “67 (20.6)” | “15 (4.7)” |
| Nausea | “37 (11.4)” | “2 (0.6)” |
| Urinary hesitation | “29 (8.9)” | “1 (0.3)” |
| Constipation | “17 (5.2)” | “4 (1.3)” |
| Somnolence | “17 (5.2)” | “10 (3.1)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.7.1-5"></a>

###### LunAIRo: adverse events

> “Adverse events (AEs) were predominantly mild, with ≥1 AE reported by 272 (82.9%) participants with AD109 and 223 (68.2%) with PBO. The most common AEs with AD109 (≥5% of participants and >PBO) were dry mouth, insomnia, nausea, urinary hesitation, somnolence, headache, dyspepsia, urinary tract infection, constipation, and dizziness. No treatment-related serious AEs were identified.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-2.1.2.7.1-6"></a>

###### Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26

> “TEAEs leading to treatment discontinuation by Week 26 was 25.0% (163/653) in participants receiving AD109 and 6.7% (43/646) receiving PBO.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-2.1.2.7.1-7"></a>

###### Pooled phase 3 analysis: overall treatment discontinuation by week 26

> “Treatment was discontinued by Week 26 in 227 (35.2%) participants randomized to AD109 and 100 (15.5%) to PBO.”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

<a id="topic-2.1.2.7.1-8"></a>

###### Treatment discontinuation due to adverse events and overall treatment discontinuation, SynAIRgy and LunAIRo

> “In SynAIRgy, among participants randomized in the main cohort, AEs led to treatment discontinuation prior to month 6 in 21.2% of participants receiving AD109 compared with 3.1% on placebo, contributing to overall discontinuation rates of 34.6% for AD109 and 16.5% for placebo at month 6. In LunAIRo, among participants randomized in the main cohort, AE–related discontinuation occurred in 23.7% of participants receiving AD109 and 6.6% receiving placebo by month 6, and remained the most common reason for discontinuation by month 12 (28.6% vs 10.0%), contributing to overall discontinuation rates of 46.5% for AD109 and 25.1% for placebo at month 12.”
> “Importantly, for both trials, AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure 32).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-9"></a>

###### SynAIRgy: adverse events leading to treatment discontinuation

> “The primary (occurring in  ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

| Treatment-emergent adverse event leading to treatment discontinuation | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
| --- | --- | --- |
| Insomnia | “16 (4.9)” | “0” |
| Urinary hesitation | “8 (2.5)” | “0” |
| Nausea | “7 (2.2)” | “0” |
| Erectile dysfunction/sexual dysfunction | “5 (1.5)” | “0” |
| Dry mouth | “4 (1.2)” | “0” |
| Hypertension | “3 (0.9)” | “0” |
| Palpitations | “3 (0.9)” | “0” |
| Urinary retention | “2 (0.6)” | “0” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.7.1-10"></a>

###### Insomnia: discontinuation, onset, duration, and severity in the phase 3 trials

> “Insomnia was the main reason for discontinuation in 4.9% of participants in SynAIRgy and 3% of participants in LunAIRo. Insomnia was not assessed at baseline in a standardized manner in the Phase 3 program for SynAIRgy.”
> “The median time of first onset for insomnia was a median (IQR) of 3 days (1 to 12) and the duration of the first event was 16 (6 to 67) days. Insomnia was mild for 79.2% of cases, moderate for 17.4% and severe for 3.4%.”
> “Oxnimbi has been shown to cause undesirable side effects, such as its ability to cause or worsen insomnia.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-11"></a>

###### Cardiovascular effects: major adverse cardiovascular events and 24-hour ambulatory blood pressure in the phase 3 trials

> “Across the pooled tolerability dataset, no (n=0) MACE were reported in participants receiving AD109. Five (n=5) MACE were reported in participants receiving placebo. The LunAIRo study included an assessment of 24-hour monitoring of ambulatory blood pressure at week 4, demonstrating small changes in mean arterial pressure (1.9 mmHg) and heart rate (4.6 bpm).”
> “Overall, changes in blood pressure and heart rate were small although a small subgroup of participants showed tachycardia while on AD109.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-12"></a>

###### Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set

| Measure | AD109 (n = 653) | Placebo (n = 646) | P value |
| --- | --- | --- | --- |
| Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD) | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD) | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.9 (12.0)” | “-1.2 (12.3)” | Not reported |
| Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.7 (8.4)” | “-1.5 (7.8)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-13"></a>

###### Cardiovascular effects: overnight heart rate over 4 weeks (MARIPOSA)

> “Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.7.1-14"></a>

###### Cardiovascular effects: populations excluded from the phase 3 trials and suggested caution

> “However, while these changes were small on average, their clinical relevance may vary depending on individual patient characteristics, and careful consideration may be warranted in patients with uncontrolled or resistant hypertension, heart failure, or tachyarrhythmias. Notably, such patients were excluded from the clinical trials.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.7.1-15"></a>

###### Adverse events of special interest in the phase 3 trials

> “Adverse events of special interest include urinary issues, cardiovascular symptoms, suicidal ideation, daytime sleepiness, motor vehicle accidents, and anticholinergic effects, with a focus on recording patient-reported experiences.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.7.1-16"></a>

###### Attribution of adverse events to the noradrenergic and antimuscarinic components

> “The adverse event profile is consistent with the mechanism of action of AD109. Noradrenergic stimulation may contribute to wake-promoting effects, including insomnia and nausea, while antimuscarinic activity may explain anticholinergic symptoms such as urinary hesitancy and dry mouth.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.7.1-17"></a>

###### Phase 1 tolerability (APC-001 and APC-002)

> “In Study APC-001 and APC-002 there were no SAEs, study drug-related treatment emergent (TE) AEs leading to study drug discontinuation or interruption.”
> “In Study APC-002 the most common TEAE was nausea, which was experienced by six subjects (26.1%) treated with AD109. Other common TEAEs included vomiting, dizziness, dry mouth, flushing, asthenia, and COVID-19.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-18"></a>

###### Meta-analysis of atomoxetine combination trials: adverse events, dry mouth, and difficulty with urination

> “While the ato group resulted in a significant increase in total AEs (RR = 1.65, 95% CI = 1.28, 2.13, P = 0.0001, I2 = 7%), dry mouth (29.2% vs 9.5%, P = 0.002) and difficulty with urination (10.7% vs 0.8%, P = 0.05).”

Source: [Zhao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42269187/)

<a id="topic-2.1.2.7.1-19"></a>

###### Atomoxetine label: boxed warning for suicidal thoughts and behaviors in children and adolescents 6 years of age and older

> “All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes.”
> “STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies.”
> “A similar analysis in adult patients treated with STRATTERA for ADHD did not reveal an increased risk of suicidal ideation or behavior.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-20"></a>

###### Atomoxetine label: contraindications

> “Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI)”
> “With narrow angle glaucoma. In clinical trials, STRATTERA use was associated with an increased risk of mydriasis.”
> “With pheochromocytoma or a history of pheochromocytoma.”
> “With severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had a clinically important increase in blood pressure or heart rate (e.g., 15 to 20 mm Hg in blood pressure or 20 beats per minute in heart rate)”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-21"></a>

###### Atomoxetine label: severe liver injury

> “STRATTERA should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury.”
> “Postmarketing reports indicate that STRATTERA can cause severe liver injury.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-22"></a>

###### Atomoxetine label: serious cardiovascular reactions

> “Consideration should be given to not treating adults with STRATTERA with clinically significant cardiac abnormalities.”
> “Adults: Sudden deaths, stroke, and myocardial infarction have been reported in STRATTERA-treated adults at the recommended ADHD dosage.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-23"></a>

###### Atomoxetine label: increases in blood pressure and heart rate

> “STRATTERA should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.”
> “Heart rate and blood pressure should be measured at baseline, following STRATTERA dosage increases, and periodically while on therapy to detect possible clinically important increases in heart rate and blood pressure.”
> “In placebo-controlled adult ADHD studies, tachycardia was identified as an adverse reaction in 1.5% (8/540) of STRATTERA-treated patients compared with 0.5% (2/402) of placebo-treated patients.”
> “Orthostatic hypotension and syncope have been reported in STRATTERA-treated patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-24"></a>

###### Atomoxetine label: psychotic or manic symptoms, bipolar disorder screening, and aggressive behavior

> “If psychotic or manic symptoms occur, consider discontinuing STRATTERA.”
> “Patients with bipolar disorder or risk factors for bipolar disorder may be at increased risk of developing mania or mixed episodes during treatment with STRATTERA.”
> “There is evidence that STRATTERA may cause the emergence or worsening of aggressive behavior or hostility.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-25"></a>

###### Atomoxetine label: effects on urine outflow

> “A complaint of urinary retention or urinary hesitancy should be considered potentially related to STRATTERA. In adult ADHD controlled studies, the incidence of urinary retention (1.7%, 9/540) and urinary hesitation (5.6%, 30/540) were increased among STRATTERA-treated patients compared with placebo-treated patients (0%, 0/402; 0.5%, 2/402, respectively).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-26"></a>

###### Atomoxetine label: priapism and hypersensitivity reactions

> “Prompt medical attention is required in the event of suspected priapism in STRATTERA-treated patients.”
> “Although uncommon, hypersensitivity reactions, including anaphylaxis, angioneurotic edema, urticaria, and rash, have been reported in STRATTERA-treated patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-27"></a>

###### Atomoxetine label: somnolence and driving

> “Patients should be instructed to use caution when driving a car or operating hazardous machinery (because of somnolence) until they are reasonably certain that their performance is not affected by STRATTERA.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-28"></a>

###### Atomoxetine label: adverse reactions and discontinuation in adult ADHD studies

> “11.3% (61/541) STRATTERA-treated patients and 3% (12/405) placebo-treated patients discontinued for adverse reactions.”
> “The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients) were: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation (see Table 5).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

| Adverse reaction in acute adult ADHD studies (up to 25 weeks) | STRATTERA (N=1,697) | Placebo (N=1,560) |
| --- | --- | --- |
| Nausea | “26%” | “6%” |
| Dry mouth | “20%” | “5%” |
| Insomnia | “15%” | “8%” |
| Urinary hesitation | “6%” | “1%” |

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-29"></a>

###### Oxybutynin label: contraindications

> “DITROPAN XL® is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-30"></a>

###### Oxybutynin label: angioedema

> “Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-31"></a>

###### Oxybutynin label: anticholinergic central nervous system effects

> “A variety of CNS anticholinergic effects have been reported, including hallucinations, agitation, confusion and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly in the first few months after beginning treatment or increasing the dose.”
> “If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.”
> “DITROPAN XL® should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-32"></a>

###### Oxybutynin label: myasthenia gravis and autonomic neuropathy

> “DITROPAN XL® should be used with caution in patients with myasthenia gravis due to the risk of aggravation of symptoms.”
> “DITROPAN XL® should be used with caution in patients with autonomic neuropathy due to the risk of aggravation of symptoms of decreased gastrointestinal motility.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-33"></a>

###### Oxybutynin label: urinary retention and gastrointestinal adverse reactions

> “DITROPAN XL® should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention”
> “DITROPAN XL®, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-34"></a>

###### Oxybutynin label: most common adverse reactions

> “The most common (incidence ≥5%) adverse reactions were dry mouth, constipation, diarrhea, headache, somnolence, and dizziness.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria

> “The targeted study population is adults (≥18 years old, no upper age limit) with OSA of any severity defined as an AHI4>5 events/h (hypopneas scored when associated with 4% desaturation) with ≤25% central or mixed apneas (as proportion of total apneas and hypopneas), and PLM arousal index ≤15 events/h on the screening PSG.”
> “Potential participants with clinically significant or medically uncontrolled cardiovascular disease such as unstable atrial fibrillation, untreated or unstable coronary artery disease, heart failure, cerebrovascular events and resting heart rate >100 beats per min or blood pressure greater than 145/90 mmHg were excluded.”
> “Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying”
> “Narrow angle glaucoma”
> “Women who are pregnant or nursing”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.8-2"></a>

###### Older men: age limits in the earlier trials because of urinary risk

> “The trials reported above excluded male patients >65 due to concerns for higher risk of urinary problems with ato-oxy or AD109 in the older male population. Women over 65 years of age were allowed in the trial without any reported safety concerns.”

Source: [Taranto-Montemurro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12713960/)

> “Age requirement was 18–65 years for men and 18–75 for women.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.8-3"></a>

###### Subgroups by sex, weight class, and baseline severity in SynAIRgy

> “In supportive analyses, AD109 improved AHI across diverse subgroups, such as those defined by sex, weight class, and baseline OSA severity (mild, moderate, and severe), supporting the generalizability of study findings to a broad spectrum of patients with OSA.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.8-4"></a>

###### Reduced CYP2D6 activity: proposed contribution to variability in tolerability

> “Tolerability may also have been influenced by interindividual variability in atomoxetine metabolism related to cytochrome P450 2D6 (CYP2D6) status. Individuals with reduced CYP2D6 activity may have higher systemic exposure to atomoxetine, which could contribute to variability in adverse events such as insomnia as well as in heart rate and blood pressure responses.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.8-5"></a>

###### Atomoxetine label: CYP2D6 poor metabolizers

> “Atomoxetine plasma concentrations were higher in CYP2D6 poor metabolizers which may increase the risk of STRATTERA-related adverse reactions.”
> “The prevalence of CYP2D6 poor metabolizers is approximately 7% in White populations, 2% in Asian populations, and 2% in Black or African American populations.”
> “Consider genetic testing to determine the patient’s CYP2D6 metabolizer status.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Atomoxetine label: hepatic impairment

> “The recommended dosage in patients with moderate or severe hepatic impairment is lower than in patients with normal hepatic function”
> “Moderate HI (Child-Pugh Class B), the recommended initial and target STRATTERA dosage is 50% of the recommended dosage in patients with normal hepatic function”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

###### Atomoxetine label: renal impairment

> “Patients with severe renal impairment (end stage renal disease requiring hemodialysis) had higher systemic atomoxetine exposure (about a 65% increase) than patients with normal renal function (CrCl ≥ 90 ml/minute) in other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate), but there was no difference when exposure was corrected for mg/kg dose. Thus, the differences in exposure were not clinically significant.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

###### Atomoxetine label: geriatric use

> “The safety, efficacy and pharmacokinetics of STRATTERA in geriatric patients have not been evaluated. Clinical studies of STRATTERA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-9"></a>

###### Atomoxetine label: pregnancy and lactation

> “Available published studies with STRATTERA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Some animal reproduction studies of atomoxetine had adverse developmental outcomes.”
> “There are no data on the presence of atomoxetine or its metabolite in human milk, the effects on the breastfed child, or the effects on milk production.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.8-10"></a>

###### Oxybutynin label: geriatric use

> “The rate and severity of anticholinergic effects reported by patients less than 65 years old and those 65 years and older were similar. The pharmacokinetics of DITROPAN XL® were similar in all patients studied (up to 78 years of age).”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.8-11"></a>

###### Oxybutynin label: renal and hepatic impairment

> “There were no studies conducted with DITROPAN XL® in patients with renal impairment.”
> “There were no studies conducted with DITROPAN XL® in patients with hepatic impairment.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.8-12"></a>

###### Oxybutynin label: pregnancy and lactation

> “There are no adequate data on DITROPAN XL® use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
> “There are no data on the presence of oxybutynin in human milk, the effects on the breastfed infant, or the effects of DITROPAN XL® on milk production.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on AD109

<a id="topic-2.1.2.9.1-1"></a>

###### Medications disallowed and allowed in the phase 3 trials

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

| Medication status in the phase 3 trials | Medications |
| --- | --- |
| Disallowed | “MAOIs, NRIs, and TCAs” |
| Disallowed | “Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” |
| Disallowed | “Muscle relaxants (in people ages >65 years), pressor agents, central agonist antihypertensives, and amphetamines” |
| Disallowed | “Oral anticholinergics, and cholinesterase inhibitors” |
| Disallowed | “Modafinil, armodafinil, solriamfetol, and pitolisant” |
| Allowed | “Antihypertensives (except central agonist)” |
| Allowed | “Inhaled corticosteroid, and antidiabetics, including those associated with weight loss” |

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.9.1-2"></a>

###### GLP-1 receptor agonists: exposure to aroxybutynin and atomoxetine (APC-APN-201)

> “This was an open-label, parallel-arm, 6-week phase 2 study of AD109 in participants with mild-to-severe OSA and obesity, administered either alone or while remaining on a stable maintenance dose of a GLP-1 RA (tirzepatide, semaglutide, or liraglutide).”
> “Geometric mean ratios (GMR; AD109+GLP-1 RA/AD109 alone [90% CI]) of aroxybutynin for Cmax, AUClast, and AUCinf were 100.6 (68.0–148.8), 142.0 (102.1–197.5), and 152.7 (111.0–210.1), respectively. GMR of atomoxetine for Cmax, AUClast, and AUCinf were 67.0 (51.0–88.1), 81.9 (57.0–117.7), and 78.2 (51.3–119.1), respectively.”
> “AD109 was generally safe and well-tolerated in both treatment arms of this phase 2 trial, without large differences in PK when co-administered with GLP-1 RA.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-2.1.2.9.1-3"></a>

###### Atomoxetine label: strong CYP2D6 inhibitors

> “With concomitant use of STRATTERA and a strong CYP2D6 inhibitor, increase the titration interval”
> “Concomitant use of STRATTERA (20 mg BID for 5 days) with paroxetine (20 mg QD for 17 days), a known inhibitor of CYP2D6, in subjects who were not CYP2D6 poor metabolizers resulted in a 6.5-fold higher plasma exposure (AUC) to atomoxetine at steady state.”
> “After concomitant use of STRATTERA with paroxetine or fluoxetine, the Css, max of atomoxetine was about 3-to 4-fold greater than the use of STRATTERA alone”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-4"></a>

###### Atomoxetine label: monoamine oxidase inhibitors

> “STRATTERA is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue, or in patients who stopped an MAOI within 14 days.”
> “As with other drugs affecting brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability with fluctuations of vital signs, extreme agitation progressing to delirium/coma) with concomitant use of STRATTERA and an MAOI.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-5"></a>

###### Atomoxetine label: drugs that affect gastric pH and drugs highly bound to plasma protein

> “Drugs that elevate gastric pH had no effect on atomoxetine bioavailability.”
> “Similarly, warfarin, acetylsalicylic acid, phenytoin, or diazepam did not affect the binding of atomoxetine to human albumin.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-6"></a>

###### Oxybutynin label: CYP3A4 inhibitors

> “Mean oxybutynin plasma concentrations were approximately 2 fold higher when DITROPAN XL® was administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.9.1-7"></a>

###### Oxybutynin label: other anticholinergic drugs

> “The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of AD109 on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Atomoxetine label: albuterol and other beta2 agonists

> “Increase the frequency of monitoring blood pressure and heart rate and adjust STRATTERA dosage as clinically appropriate.”
> “Systemically administered albuterol (e.g., oral) can be potentiated by atomoxetine, resulting in increases in heart rate and blood pressure.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### Atomoxetine label: antihypertensive drugs and pressor agents

> “Increase the frequency of monitoring blood pressure and adjust STRATTERA dosage as clinically appropriate.”
> “Because of increased risk of increased blood pressure, STRATTERA should be used cautiously with antihypertensive drugs, other drugs that increase blood pressure or pressor drugs (e.g., dopamine, dobutamine).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-3"></a>

###### Atomoxetine label: CYP3A and CYP2D6 substrates and cytochrome P450 inhibition

> “Concomitant use of STRATTERA (60 mg twice daily for 12 days) with midazolam (CYP3A substrate) (single dose of 5 mg), resulted in 15% increase in the midazolam AUC. This pharmacokinetic change is not clinically significant.”
> “Concomitant use of STRATTERA (40 or 60 mg twice daily for 13 days) with desipramine, (CYP2D6 substrate) (single dose of 50 mg), did not alter the desipramine pharmacokinetics.”
> “Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes (including CYP1A2, CYP3A, CYP2D6, and CYP2C9).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-4"></a>

###### Atomoxetine label: ethanol, methylphenidate, and drugs highly bound to plasma protein

> “Consumption of ethanol with STRATTERA did not change the intoxicating effects of ethanol.”
> “Concomitant use of STRATTERA with methylphenidate did not increase cardiovascular effects beyond those seen with methylphenidate alone.”
> “Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-5"></a>

###### Oxybutynin label: absorption of concomitant drugs and prokinetic agents

> “Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 regimen: 1-week run-in dose followed by the target dose, with no dose reduction

> “AD109 dose was aroxybutynin 2.5 mg/atomoxetine 37.5 mg for week 1 and aroxybutynin 2.5 mg/atomoxetine 75 mg for the remaining weeks (dose reductions not permitted).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”
> “Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.10.1-2"></a>

###### Company statement on dose adjustment for tolerability in clinical practice

> “A lower dose of AD109 (2.3/37.5mg) was administered during the one-week run-in period; however, dose reduction was not permitted in the Phase 3 trials, to maximize evaluation of efficacy. The same lower dose demonstrated improvements in AHI in a prior trial in milder OSA (Figure 9). We believe dose adjustment may be considered in clinical practice, if AD109 is approved, to address tolerability.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “In addition, participants who experienced a higher incidence of AEs may have benefited from a lower, efficacious dose of AD109.30 However, dose reduction was not allowed in the trial.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.10.1-3"></a>

###### Atomoxetine dose relative to the maximum recommended ADHD dose

> “The highest dose of atomoxetine that is being considered for Oxnimbi is 75mg, which is lower than the maximum recommended dose for ADHD of 100mg per day.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.10.1-4"></a>

###### Higher aroxybutynin dose (5/75 mg) in dose finding (MARIPOSA)

> “It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Once nightly at bedtime (company description)

> “Oxnimbi is formulated into a small tablet that is taken once nightly, just prior to bedtime.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 is intended to be a once-daily oral pill taken at bedtime that is designed to lower the complexity of treating OSA.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration in the clinical trials

> “Participants take the run-in dose nightly at home and return with the bottle and empty blister pack at V4 for IMP accountability.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “Participants were instructed to take the study drug nightly immediately before bedtime for 4 weeks.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.10.2-3"></a>

###### Atomoxetine label: administration with respect to food

> “STRATTERA may be taken with or without food. Take STRATTERA capsules whole; do not open the capsules.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.10.2-4"></a>

###### Oxybutynin label: administration of the extended-release tablet with respect to food

> “DITROPAN XL® must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed. DITROPAN XL® may be administered with or without food.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial readiness activities before a potential launch

> “Continued to advance commercial readiness activities, including market access and payer engagement, commercial team and go-to-market build-out, and manufacturing and distribution preparation, to support a potential U.S. launch of Oxnimbi, subject to FDA approval.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.11-2"></a>

###### Payer discussions to inform potential 2027 formulary inclusion

> “Market Access & Reimbursement. We are conducting payer information exchanges and engaging in early, non-binding formulary contracting discussions with leading Medicare Part D and Commercial payers to inform potential 2027 formulary inclusion for Oxnimbi, subject to FDA approval. These activities are designed to understand evidence requirements, anticipated utilization management approaches, and potential pathways for future coverage.”
> “Market research conducted by us among payers suggested that payers see a clear unmet need in OSA, as current OSA therapies are not curative and do not address the root cause of OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-3"></a>

###### Planned distribution model: specialty pharmacy partners and a patient services hub

> “Distribution and Patient Access Infrastructure. Subject to approval, we expect to utilize a distribution model that includes specialty pharmacy partners and centralized patient support services to facilitate access, benefits investigation, and reimbursement navigation, as needed. Our distribution strategy is intended to be developed in alignment with payer requirements, pharmacy network design, and anticipated utilization management approaches for OSA therapies. We also plan to establish a patient services hub to support prior authorization processes, affordability programs, and care coordination as needed, consistent with industry standards.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-4"></a>

###### Planned field sales force and prescriber targets

> “Field Sales and Provider Engagement. We expect to deploy a targeted field sales organization of 125 to 150 representatives focused initially on covering 15,000 to 20,000 sleep specialists and high-volume primary care practices that manage patients with OSA. We also expect to deploy a small team targeting key OSA accounts and health systems.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Planned Oxnimbi Promotional Launch Model”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.1.2.11-5"></a>

###### Planned launch sequence by patient segment

> “We intend to focus our initial launch phase of Oxnimbi, if approved, on the approximately 10.5 million people in the United States who are diagnosed with OSA but untreated, estimated based on the results of a survey conducted by the National Sleep Foundation in 2025”
> “Our long-term target market is patients seeking initial treatment, with Oxnimbi as a first-line solution, and analogs suggest that oral therapies are likely to evolve into first-line treatments over time.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-6"></a>

###### Planned telehealth care pathways and durable medical equipment provider engagement

> “Subject to regulatory approval, we intend to partner with health systems, specialty telehealth providers, and virtual diagnostic platforms to support appropriate patient evaluation, diagnosis, and treatment initiation.”
> “If Oxnimbi is approved, we plan to engage where possible with DME organizations to help identify patients who are unable to initiate or sustain PAP therapy and who may require further clinical evaluation by their healthcare providers.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-7"></a>

###### Manufacturing and commercial supply: contract manufacturers, no commercial supply agreements signed

> “We do not own or operate any manufacturing facilities.”
> “In the future, if Oxnimbi or any future product candidates are approved, we plan to enter into manufacturing and supply agreements with CMOs to support commercial scale production, but we do not have commercial supply agreements signed at this time.”
> “We have qualified primary and secondary suppliers for our API components of Oxnimbi, which have demonstrated adequate scale for our commercial supply needs and utilized these suppliers in our pre-commercial clinical studies supply program and registration stability batches.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.11-8"></a>

###### Launch financing

> “$351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

> “The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA).”

Source: [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Positive airway pressure: initiation permitted during the phase 3 trials

> “Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.12-2"></a>

###### Allowed and disallowed concomitant medications in the phase 3 trials

> “Inhaled corticosteroid, and antidiabetics, including those associated with weight loss”
> “Drugs used exclusively for weight loss”
> “Modafinil, armodafinil, solriamfetol, and pitolisant”
> “Benzodiazepines, Z-drugs, DORAs, and trazodone”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.12-3"></a>

###### GLP-1 receptor agonists: pooled phase 3 exploratory analysis of weight change, participants taking a GLP-1 receptor agonist for diabetes

> “Participants receiving GLP-1 RA for diabetes were permitted.”
> “One-hundred and six participants were enrolled in the phase 3 trials taking a GLP-1 RA for diabetes (PBO+GLP-1 RA: n=48; AD109+GLP-1 RA: n=58).”
> “In participants receiving a GLP-1 RA with baseline BMI ≥35, AD109 reduced weight by 5.5% (vs PBO: 0.9%, P=0.02) and 11.5% (vs PBO: 3.8%, P=0.04) at Week 26 and Week 51, respectively.”

Source: [Strollo et al. (2026a)](https://academic.oup.com/sleep/article/49/Supplement_1/A261/8673726)

<a id="topic-2.1.2.12-4"></a>

###### GLP-1 receptor agonists: company summary of concomitant use in the phase 3 trials

> “A subset of participants in the Phase 3 SynAIRgy and LunAIRo trials were receiving concomitant GLP-1 receptor agonists at stable doses, most commonly semaglutide. Across these trials, the effects of AD109 on AHI reduction were directionally similar in participants receiving GLP-1 therapy and those not receiving GLP-1 therapy, suggesting that the treatment effect of AD109 was additive to GLP-1 use in participants on stable doses.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.12-5"></a>

###### GLP-1 receptor agonists for weight loss: SynAIRgy exploratory cohort not analyzed

> “Due to low enrollment in this cohort, the prespecified exploratory analyses are not included in this report.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.12-6"></a>

###### GLP-1 receptor agonists: open-label phase 2 co-administration study

> “Forty participants were enrolled and received AD109 (n=22) or AD109+GLP-1 RA (n=18).”
> “AD109 was generally safe and well-tolerated in both treatment arms of this phase 2 trial, without large differences in PK when co-administered with GLP-1 RA.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-2.1.2.12-7"></a>

###### Intended use alongside PAP or GLP-1 therapy

> “Thereafter, we intend to focus on patients using another treatment who have not fully resolved their OSA, for example, providing Oxnimbi as a compliment to PAP or GLP-1s.”
> “A Wells Fargo survey conducted in August of 2025 reported that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it, if approved, either as a first-line therapy, after PAP or together with PAP”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of AD109 on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### Merit-based Incentive Payment System 2026 measure 279: assessment of adherence to obstructive sleep apnea therapy

> “Percentage of patients aged 18 years and older with a diagnosis of obstructive sleep apnea (OSA) that were prescribed an evidence-based therapy that had documentation that adherence to therapy was assessed at least annually through an objective informatics system or through self-reporting (if objective reporting is not available).”
> “Evidence-based Therapy – includes positive airway pressure, oral appliances, positional therapies, hypoglossal nerve stimulation, or other devices with monitoring capabilities.”
> “Objective Informatics – a telemonitoring system that shows data demonstrating patient adherence to the prescribed therapy for obstructive sleep apnea (i.e., CPAP machines with SD cards that store data).”
> “This recommendation is based on evidence that therapy adherence is extremely important for patients with OSA to experience improvement in signs and symptoms of OSA.”

Source: [CMS Quality Payment Program measure 279 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_279_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

###### Merit-based Incentive Payment System 2026 measure 277: severity assessment at initial diagnosis

> “Percentage of patients aged 18 years and older with a diagnosis of obstructive sleep apnea who had an apnea hypopnea index (AHI), a respiratory disturbance index (RDI), or a respiratory event index (REI) documented or measured within 2 months after initial evaluation for suspected obstructive sleep apnea.”

Source: [CMS Quality Payment Program measure 277 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_277_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

###### American Academy of Sleep Medicine adult obstructive sleep apnea quality measure set, 2022 update

> “Two of the measures are currently included in the Merit-based Incentive Payment System (MIPS) program, which replaced the PQRS program, as a part of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).”
> “For the purposes of this measure, evidence-based therapies include positive airway pressure, oral appliances (custom, titratable, Food and Drug Administration [FDA]–cleared appliances), positional therapies, upper airway surgeries, hypoglossal nerve stimulation.”
> “Proportion of patients aged 18 years and older diagnosed with OSA that showed any improvement in their quality of life (QoL) from baseline within 1 year of starting treatment.”
> “The Task Force reviewed this measure and agreed that, although there is not yet convergence on exactly which HRQoL instrument should be used, this is an important outcome to measure and document, as it will speak to the effectiveness of the assessments and treatment captured in the process measures.”
> “The registry is approved by CMS as a Qualified Clinical Data Registry, for reporting quality measures as a part of the Quality Payment Program, a national quality reporting initiative that includes MIPS.”

Source: [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9622990/)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Head-to-head and indirect comparisons of AD109 with other OSA treatments

No evidence found.

<a id="topic-2.1.2.14-2"></a>

###### Cross-trial context for AD109 and tirzepatide in an editorial on SynAIRgy

> “In the SURMOUNT-OSA trials, tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist, produced substantially larger reductions in AHI than AD109, although direct comparisons are limited by important differences in study populations, including markedly higher baseline AHI and body mass index in SURMOUNT-OSA and greater potential for placebo effect.”
> “Whereas tirzepatide primarily targets metabolic contributors to airway collapse through weight reduction and is therefore most applicable to patients with obesity, AD109 targets upper airway neuromuscular dysfunction and may have applicability across a broader spectrum of patients with OSA.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.1.2.14-3"></a>

###### Comparator: tirzepatide in moderate-to-severe OSA with obesity, AHI with 4% desaturation hypopnea rule

> “which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%”
> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.1.2.14-4"></a>

###### Review comparison of OSA pharmacotherapies, SynAIRgy figures under the treatment policy estimand

> “Although AD109 demonstrated statistically significant therapeutic efficacy compared with placebo, the reductions in the AHI and oxygen desaturation index were only 3.3/h and 3.7/h, respectively.”
> “These findings suggest that long-term tolerability and safety may remain challenging [28].”
> “Although tirzepatide is currently the only U.S. Food and Drug Administration-approved medication for OSA, it is expected that OSA-directed pharmacotherapy unrelated to weight loss that is effective for patients who refuse or discontinue PAP therapy may become available in the near future.”

Source: [Kim (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434379/)

<a id="topic-2.1.2.14-5"></a>

###### Investigational comparator: sulthiame in the FLOW phase 2 trial, AHI with 3% desaturation or arousal hypopnea rule

> “Adults (aged 18–75 years) with untreated, moderate to severe OSA and an Apnoea–Hypopnea Index (AHI) of ≥15 to ≤50 events per h were randomly assigned (1:1:1:1), using interactive response technology, to receive placebo or sultiame 100 mg, 200 mg, or 300 mg tablets of identical appearance once per day at bedtime for 15 weeks.”
> “In the full analysis set, placebo-subtracted relative AHI3a adjusted means change at week 15 was –16·4% (95% CI –31·3 to –1·4; p=0·032), –30·2% (–45·4 to –15·1; p<0·0001), and 34·6% (–49·1 to –20·0; p<0·0001) for sultiame 100 mg, 200 mg, and 300 mg, respectively.”
> “Events reported in more than 10% of patients in the placebo, 100 mg, 200 mg, or 300 mg groups were paraesthesia (seven [9%] of 75, 16 [22%] of 74, 32 [43%] of 74, 43 [57%] of 75), headache (six [8%], five [7%], 12 [16%], 11 [15%]), COVID-19 (three [4%], three [4%], six [8%], ten [13%]), and nasopharyngitis (nine [12%], three [4%], seven [9%], seven [9%]).”

Source: [Randerath et al. (2025)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01196-1/fulltext)

<a id="topic-2.1.2.14-6"></a>

###### Sulthiame rights transferred from Apnimed to Shionogi

> “In April 2026, we completed the SASS Disposition pursuant to the MIPA and concurrently all of our rights and obligations under the Desitin APA were transferred to Shionogi.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.14-7"></a>

###### Investigational comparator: IHL-42X (dronabinol and acetazolamide) in the RePOSA phase 2 portion

> “The study enrolled 121 subjects across 16 clinical trial sites in the United States and was conducted in accordance with an IND cleared by the FDA.”
> “The low-dose and high-dose IHL-42X groups achieved a statistically significant reduction in percent change in AHI from baseline compared to placebo (p<0.05), the primary measure of OSA severity.”
> “Notably, 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved a greater than 30% reduction in AHI, while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%, demonstrating a strong therapeutic response in a substantial subset of the population.”
> “The DReAMzz Study commenced in May 2026, with screening beginning in July 2026. The next major milestone is completion of the DReAMzz Study, estimated for mid-2027, followed by analysis to inform dose selection and the planned Phase 3 design.”
> “Competitors in the OSA drug development space include Apnimed, Inc. and Mineralys Therapeutics.”

Source: [Incannex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/ixhl-20260630.htm)

<a id="topic-2.1.2.14-8"></a>

###### Hypoglossal nerve stimulation manufacturer statement on AD109 as a competing product

> “The product is in phase 3 clinical development.”
> “In Europe, the Genio system is CE-Mark certified for use as a second-line therapy in the treatment of moderate to severe OSA in patients who do not tolerate, refused or failed positive airway pressure, or PAP, therapy.”

Source: [Nyxoah Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1857190/000110465926035161/nyxh-20251231x20f.htm)

<a id="topic-2.1.2.14-9"></a>

###### Manufacturer description of competing treatments

> “We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is targeted to a subset of OSA patients.”
> “There are also several programs in clinical and preclinical development to treat OSA by pharmaceutical companies including Kyorin Pharmaceutical Co., Ltd., Incannex Healthcare Ltd. and Mosanna Therapeutics.”
> “Tirzepatide targets the weight-related anatomical cause of OSA. It does not address the underlying neuromuscular cause of OSA. This therapy is relevant for less than approximately 20% of the total OSA population, as it is not indicated for patients without obesity or for those with mild OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

Additional sources: [Hedner et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35202553/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: upper airway collapse during sleep with apneas and hypopneas

> “Obstructive sleep apnea (OSA) is the most common type of sleep disordered breathing (SDB).”
> “OSA is characterized by upper airway collapse during sleep resulting in partial or complete interruption of airflow (i.e., respiratory events including apneas and/or hypopneas that may be associated with oxygen desaturation, hypercapnia, and/or arousals and sleep fragmentation).”
> “Hypopnea is a 30% or greater decrease in airflow that is at least 10 seconds in duration and is associated with either a ≥3% oxygen desaturation or arousal.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-2"></a>

###### Definition: narrowing of the upper airway that impairs ventilation during sleep

> “This paper focuses on diagnostic issues related to the diagnosis of OSA, a breathing disorder characterized by narrowing of the upper airway that impairs normal ventilation during sleep.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.1-3"></a>

###### Diagnostic criteria: ICSD-3-TR criteria reproduced in the VA/DoD guideline

> “((A and B) or C) + D must be met”
> “The patient complains of sleepiness, fatigue, insomnia, or other symptoms leading to impaired sleep-related quality of life.”
> “The patient wakes with breath holding, gasping, or choking”
> “Five or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT)”
> “Fifteen or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT)”
> “The symptoms are not better explained by another current sleep disorder, medical disorder, medication or substance use.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-4"></a>

###### Diagnostic criteria: ICSD-3 definition and variability in the hypopnea definition

> “The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).”
> “However, it should be noted that there is variability in the definition of a hypopnea event.”
> “Depending on which definition is used, the AHI may be considerably different in a given individual.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.1-5"></a>

###### Severity categories by respiratory event index

> “Mild OSA is defined as ≥5 to <15 events per hour with the presence of symptoms; moderate OSA is defined as ≥15 to <30 events per hour; and severe OSA is defined as ≥30 events per hour.”
> “However, the apnea-hypopnea index (AHI) or respiratory event index (REI) are not the sole indicators of OSA severity in a given patient, as this parameter does not account for oxygen desaturation frequency or oxygen saturation nadir, the duration of the respiratory event, sleep fragmentation, or comorbid illnesses.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-6"></a>

###### Risk factors: age, sex, body mass index, and menopause

> “The prevalence of OSA increases with age, body mass index (BMI), and males (2:1), but after menopause the risk in women increases.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.1-7"></a>

###### Risk factors: demographic, anatomical, and behavioral factors

> “OSA incidence and prevalence is expected to rise with obesity rates; however, it is not solely related to obesity.”
> “Obstructive sleep apnea is more prevalent in individuals with factors that include being older, male, a minority race, have a high body mass index, large neck circumference, craniofacial abnormalities, are menopausal, and those with health behaviors such as smoking and alcohol use.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.1-8"></a>

###### Risk factors: high-risk clinical populations

> “High-risk patients include those who are obese, those with congestive heart failure, atrial fibrillation, treatment refractory hypertension, type 2 diabetes, stroke, nocturnal dysrhythmias, pulmonary hypertension, high-risk driving populations (such as commercial truck drivers), and those being evaluated for bariatric surgery (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.1-9"></a>

###### Obesity as a risk factor: share of adults with OSA who have obesity, AHI of 5 or more with 4% desaturation hypopnea rule (individual participant data meta-analysis with Apnimed authors)

> “Obesity is a well-established risk factor for obstructive sleep apnea (OSA).”
> “OSA severity was quantified using the apnea-hypopnea index (AHI, all apneas plus hypopneas with ≥4% oxygen desaturation/hour).”
> “Among 12,860 adults (mean ± SD age: 66.6 ± 7.3 years), 7222 (56.2%) had OSA (AHI ≥5 events/h) and 3309 (25.7%) had obesity (BMI ≥30 kg/m2).”
> “IPD meta-analysis showed 31.5% [95% CI: 16.8–48.5] of individuals with OSA had obesity and 44.4% [36.5–52.5] had overweight status (25 ≤ BMI < 30).”
> “Odds ratios for OSA in subgroups of individuals with overweight and obesity compared to BMI <25 kg/m2 were 2.18 [1.73–2.76] and 4.84 [3.09–6.00], respectively.”
> “LG, L T-M, JY, JC work for Apnimed.”

Source: [Esmaeili et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12051718/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Obstructive sleep apnea

<a id="topic-2.2.1.2.1-1"></a>

###### Five-year incidence of AHI of at least 10 and at least 15 in a US community cohort (Cleveland Family Study, in-home sleep studies)

> “Sleep-disordered breathing was defined by an AHI of at least 10 (mild to moderate) or of at least 15 (moderate).”
> “Forty-seven (16%) of 286 eligible participants, (95% confidence interval [CI], 13%-21%) had a second-study AHI of at least 10 and 29 (10%) participants (95% CI, 7%-14%) had a second-study AHI result of at least 15.”
> “The 5-year incidence is about 7.5% for moderately severe SDB and 16% (or less) for mild to moderately severe SDB.”
> “Predominance in men diminishes with increasing age, and by age 50 years, incidence rates among men and women are similar.”

Source: [Tishler et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12734134/)

<a id="topic-2.2.1.2.1-2"></a>

###### Weight change and incident moderate-to-severe sleep-disordered breathing, AHI of 15 or more (Wisconsin Sleep Cohort, 4-year intervals)

> “Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI.”
> “A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI.”
> “A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB.”

Source: [Peppard et al. (2000b)](https://pubmed.ncbi.nlm.nih.gov/11122588/)

<a id="topic-2.2.1.2.1-3"></a>

###### Five-year progression of the respiratory disturbance index with weight change (Sleep Heart Health Study)

> “Men were more likely to have an increase in Respiratory Disturbance Index (RDI) with a given increase in weight than were women, and this was not explained by differences in starting weight, waist circumference, age, or ethnicity.”
> “However, SDB progressed over time, even in those with stable weight.”

Source: [Newman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16287771/)

<a id="topic-2.2.1.2.1-4"></a>

###### Predictors of five-year change in the respiratory disturbance index (Cleveland Family Study)

> “Longitudinal change in the RDI varies nonuniformly with age, sex, and weight.”
> “Older heavier men may experience the highest rate of increase in RDI over time and, thus, may benefit most from prospective monitoring.”

Source: [Redline et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14572123/)

<a id="topic-2.2.1.2.1-5"></a>

###### Diagnosed incidence in English primary care and hospital records, 2010 to 2019 (ResMed-authored)

> “Included adults had ≥ 1 OSA code and ≥ 12 months’ medical records before/after OSA diagnosis.”
> “The incidence of OSA increased from 46.74 per 100,000 in 2010 to 91.04 per 100,000 in 2019, with an average of 65.06 per 100,000 person-years over the period.”
> “The overall diagnosed incidence of OSA was 65.06 per 100,000 person-years (95% CI, 64.57-65.54).”
> “M. D., A. G., and N. A. are employees of ResMed and are ResMed shareholders.”

Source: [Ali et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13419131/)

<a id="topic-2.2.1.2.1-6"></a>

###### Diagnosed incidence in active-component US military members, 2004 to 2015

> “The study identified 223,731 incident cases of OSA with an overall incidence rate of 139.2 per 10,000 person-years, between 2004 and 2015.”
> “Rates increased more than 3-fold between 2004 and 2015.”

Source: [Rogers et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27792352/)

<a id="topic-2.2.1.2.1-7"></a>

###### Incidence of physician-reported sleep apnea after GLP-1 or dual agonist initiation in adults with obesity or type 2 diabetes (TriNetX records)

> “We identified adult patients with obesity and/or type 2 diabetes mellitus never prescribed GLP-1 or dual agonist therapy (reference arm) and those new initiators of these medications.”
> “Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR, 0.46 [95% CI, 0.45-0.49]).”

Source: [Prado et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41915565/)

<a id="topic-2.2.1.2.1-8"></a>

###### Absence of US incidence data in a national projection model (ResMed-funded)

> “Given the scarcity of data for obstructive sleep apnoea incidence in the USA, prevalence was used as a proxy to determine incidence by sex and age group.”
> “This study was funded by Resmed.”

Source: [Boers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12674968/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Obstructive sleep apnea

<a id="topic-2.2.1.2.2-1"></a>

###### Company estimate: 80 million US adults aged 30 to 69 and one billion people worldwide (Clarivate study commissioned by Apnimed)

> “OSA is a highly prevalent condition, estimated to be affecting approximately 80 million people in the United States between the ages of 30-69, according to a study we commissioned from Clarivate Plc. (Clarivate).”
> “The total addressable market for Oxnimbi includes the estimated 80 million adults in the United States and approximately one billion people worldwide with OSA, encompassing both diagnosed and undiagnosed individuals according to a study we commissioned from Clarivate and the World Health Organization (the WHO), respectively.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-2"></a>

###### Company estimate: newly diagnosed, diagnosed and active in care, and diagnosed but untreated US adults (claims databases and a survey)

> “Each year, approximately three million people are newly diagnosed according to Komodo Health, Inc.’s (Komodo) medical claims database.”
> “Our analysis of U.S. IQVIA Holdings Inc. (NYSE: IQV) (IQVIA) claims data indicates that over a five-year period from 2019 to 2024, approximately 23 million unique patients with a diagnosis of OSA were active within the healthcare system.”
> “Research from the National Sleep Foundation indicates that approximately 10.5 million people in the United States are diagnosed with OSA but are not currently receiving treatment.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### Company estimate: new diagnosis rate and initial target population, September 2026 corporate presentation

> “New diagnosis rate >3M/year”
> “Initial target is ~10.5M diagnosed not on PAP”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.2.1.2.2-4"></a>

###### Company estimate: share of middle-aged and older adults with OSA who are not obese (third-party study supported by Apnimed)

> “A third party study, supported by certain company personnel and a grant from us in the community setting, estimates that more than 60% of middle-aged and older adults living with OSA are not obese.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-5"></a>

###### US prevalence in 2024, AHI4 of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection by Clarivate and Apnimed authors)

> “A literature-based systematic review was conducted to identify studies of OSA prevalence in adults using the AHI4 criteria (all apneas plus hypopneas associated with ≥4% oxygen desaturation).”
> “OSA was defined as having an AHI4 ≥ 5 events/hr.”
> “A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.”
> “This translates to 32.4% overall prevalence in the US among adults aged 20 years and older, with 39.1% among males and 26.0% in females, adjusting for obesity.”
> “The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.”
> “I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.”

Source: [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/)

<a id="topic-2.2.1.2.2-6"></a>

###### Self-reported diagnosed but untreated sleep apnea, US adults aged 18 to 90 (National Sleep Foundation survey with support from Inspire Medical Systems)

> “A Report from National Sleep Foundation, with Support from Inspire Medical Systems, Inc.”
> “The final sample was comprised of 1,015 American adults ages 18-90 years old (M = 48, SD = 18.21) who were representative of the US adult population (i.e., 61% White, 12% Black, and 18% Hispanic; 51% female).”
> “Of the 19% of adults who have had some form of diagnostic workup, 13% reported being diagnosed; however, 4% of those diagnosed with sleep apnea say they are not currently being treated.”
> “Stated differently, approximately 31%, or over 10.5 million adults, diagnosed with sleep apnea are not currently receiving needed treatment.”
> “Eleven percent of those who have never been tested or diagnosed have a suspicion that they likely have sleep apnea—this equates to just over 29 million people who think they might have sleep apnea.”

Source: [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf)

<a id="topic-2.2.1.2.2-7"></a>

###### US prevalence in 2007 to 2010, AHI of 5 or more and 15 or more with 4% desaturation hypopnea rule, adults aged 30 to 70 (Wisconsin Sleep Cohort extrapolated to NHANES body mass index distributions)

> “A discernible reduction in the sum of thoracic plus abdomen respiratory inductance plethysmography amplitude associated with a 4% or more reduction in oxyhemoglobin saturation defined a hypopnea event.”
> “The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.”
> “These estimated prevalence rates represent substantial increases over the last 2 decades (relative increases of between 14% and 55% depending on the subgroup).”
> “Summing over age × sex × BMI strata, we estimated the overall prevalence of mild to severe SDB (AHI ≥5) to be 26% (95% confidence interval: 24, 28) among person 30–70 years of age for the recent time period (2007–2010).”
> “Similarly, the estimated overall prevalence of moderate to worse SDB (AHI ≥15) was 10% (95% confidence interval: 8, 11).”
> “We also estimate that 14% of men and 5% of women have an AHI ≥5 plus symptoms of daytime sleepiness.”

Source: [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)

<a id="topic-2.2.1.2.2-8"></a>

###### Global prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (ResMed-funded)

> “A conversion algorithm was created for studies that did not use the American Academy of Sleep Medicine (AASM) 2012 scoring criteria to identify obstructive sleep apnoea, allowing determination of an equivalent apnoea-hypopnoea index (AHI) for publications that used different criteria.”
> “Using AASM 2012 diagnostic criteria and AHI threshold values of five or more events per h and 15 or more events per h, we estimated that 936 million (95% CI 903–970) adults aged 30–69 years (men and women) have mild to severe obstructive sleep apnoea and 425 million (399–450) adults aged 30–69 years have moderate to severe obstructive sleep apnoea globally.”
> “The number of affected individuals was highest in China, followed by the USA, Brazil, and India.”
> “AVB, KV, and CMN are employees of ResMed.”
> “Funding ResMed.”

Source: [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/)

<a id="topic-2.2.1.2.2-9"></a>

###### US prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (country table of the global estimate)

| Measure | United States |
| --- | --- |
| Population aged 30–69 years | “163 246 772” |
| AHI ≥5 events per h, n (%) | “54 131 654 (33·2%)” |
| AHI ≥15 events per h, n (%) | “23 678 109 (14·5%)” |

Source: [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/)

<a id="topic-2.2.1.2.2-10"></a>

###### US prevalence projected from 2020 to 2050, AHI of 5 or more, adults aged 30 to 69, hypopnea scoring rule not stated (ResMed-funded simulation model)

> “This study was funded by Resmed.”
> “Obstructive sleep apnoea diagnosis was based age, sex, BMI, and AHI, a metric reflecting the number of apnoea and hypopnoea events per hour of sleep,22 with individuals considered to have obstructive sleep apnoea if their AHI was 5/h or higher.”
> “By 2050, the prevalence of obstructive sleep apnoea (apnoea–hypopnoea index ≥5/h) is expected to show a relative increase of 34·7%, from 34·3% (95% uncertainty interval [UI] 34·0–34·4) to 46·2% (46·0–46·4), resulting in 76·6 million cases.”
> “Males are projected to show a more moderate relative increase of 19·3%, from 45·6% (45·4–46·0) to 54·4% (54·2–54·7), reaching 45·9 million cases.”
> “Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males.”

Source: [Boers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12674968/)

<a id="topic-2.2.1.2.2-11"></a>

###### Prevalence of AHI of 15 or more with AASM 2012 hypopnea rule, adults aged 40 to 85 in Lausanne, Switzerland (HypnoLaus)

> “We used the 2012 criteria for our analysis (because they are the most recent and currently recommended criteria) and reported the average number of apnoea and hypopnoea events per h of sleep (the apnoea-hypopnoea index).”
> “1024 (48%) participants were men, with a median age of 57 years (IQR 49–68, range 40–85) and mean body-mass index (BMI) of 25·6 kg/m2 (SD 4·1).”
> “The prevalence of moderate-to-severe sleep-disordered breathing (≥15 events per h) was 23·4% (95% CI 20·9–26·0) in women and 49·7% (46·6–52·8) in men.”

Source: [Heinzer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4404207/)

<a id="topic-2.2.1.2.2-12"></a>

###### Prevalence of an apnea-hypopnea score of 5 or more, employed Wisconsin adults aged 30 to 60 (Wisconsin Sleep Cohort, polysomnography)

> “A random sample of 602 employed men and women 30 to 60 years old were studied by overnight polysomnography to determine the frequency of episodes of apnea and hypopnea per hour of sleep (the apnea-hypopnea score).”
> “The estimated prevalence of sleep-disordered breathing, defined as an apnea-hypopnea score of 5 or higher, was 9 percent for women and 24 percent for men.”
> “We estimated that 2 percent of women and 4 percent of men in the middle-aged work force meet the minimal diagnostic criteria for the sleep apnea syndrome (an apnea-hypopnea score of 5 or higher and daytime hypersomnolence).”

Source: [Young et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8464434/)

<a id="topic-2.2.1.2.2-13"></a>

###### Range of general-population prevalence across 24 studies, AHI of 5 or more and 15 or more (systematic review)

> “Twenty-four studies out of 3807 found by systematically searching PubMed and Embase databases were included in this review.”
> “At ≥5 events/h apnea-hypopnea index (AHI), the overall population prevalence ranged from 9% to 38% and was higher in men.”
> “It increased with increasing age and, in some elderly groups, was as high as 90% in men and 78% in women.”
> “At ≥15 events/h AHI, the prevalence in the general adult population ranged from 6% to 17%, being as high as 49% in the advanced ages.”

Source: [Senaratna et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27568340/)

<a id="topic-2.2.1.2.2-14"></a>

###### Prevalence in clinical populations: bariatric surgery candidates and people with stroke or transient ischemic attack

> “In some populations, the prevalence of OSA is substantially higher than this estimate, for example, in patients being evaluated for bariatric surgery (estimated range of 70% to 80%)11 or in patients who have had a transient ischemic attack or stroke (estimated range of 60% to 70%).”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.2.2-15"></a>

###### Undiagnosed share of moderate to severe sleep apnea syndrome, employed adults in Wisconsin

> “In this population, without obvious barriers to health care for sleep disorders, we estimate that 93% of women and 82% of men with moderate to severe SAS have not been clinically diagnosed.”

Source: [Young et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9406321/)

<a id="topic-2.2.1.2.2-16"></a>

###### Diagnosed and undiagnosed US adults, AHI over 5 (Frost & Sullivan report commissioned by the AASM)

> “Frost & Sullivan was commissioned by the AASM to investigate the dynamics of sleep apnea diagnosis and treatment, and its impact on healthcare and workplace economics in the United States.”
> “Prevalence OSA (AHI>5)”
> “Frost & Sullivan estimates the prevalence of OSA to be 12% or 29.4 million of the U.S. adult population with nearly 80% of the population undiagnosed.”
> “Frost & Sullivan estimates that out of the 29.4 million U.S. adults with OSA, only 20% or 5.9 million individuals have been diagnosed.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.2.2-17"></a>

###### Diagnosed prevalence in US insured adults and children with claims activity, 2013 to 2016 (nationwide claims, Jazz Pharmaceuticals-funded)

> “Nationwide medical/prescription claims (Symphony Health) were analyzed to estimate the annual prevalence per 100,000 persons of narcolepsy and other sleep disorders (obstructive sleep apnea, idiopathic hypersomnia, rapid eye movement sleep behavior disorder, periodic limb movement disorder) and the frequency of diagnostic sleep testing.”
> “Obstructive sleep apnea prevalence increased 41% over the study period from 2,429 to 3,420 per 100,000.”
> “This study was funded by Jazz Pharmaceuticals.”

Source: [Acquavella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446073/)

<a id="topic-2.2.1.2.2-18"></a>

###### Documented sleep-related breathing disorders in Veterans Affairs outpatients, 2018

> “Similarly, a review of VA medical records revealed an increase in documented diagnoses of both OSA and insomnia, with 22% of outpatients diagnosed with sleep-related breathing disorders and 11.8% diagnosed with insomnia in 2018.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Progression with weight gain: Wisconsin Sleep Cohort, AHI as apnea plus hypopnea events per hour of sleep

> “Six hundred ninety randomly selected employed Wisconsin residents (mean age at baseline, 46 years; 56% male) who were evaluated twice at 4-year intervals for SDB.”
> “Percentage change in the apnea-hypopnea index (AHI; apnea events + hypopnea events per hour of sleep) and odds of developing moderate-to-severe SDB (defined by an AHI > or =15 events per hour of sleep), with respect to change in weight.”
> “Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI. A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI. A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB.”

Source: [Peppard et al. (2000b)](https://pubmed.ncbi.nlm.nih.gov/11122588/)

<a id="topic-2.2.1.3-2"></a>

###### Progression and regression over 5 years: Sleep Heart Health Study, respiratory disturbance index

> “A total of 2968 men and women (mean age, 62 years) participated in the study.”
> “Men were more likely to have an increase in Respiratory Disturbance Index (RDI) with a given increase in weight than were women, and this was not explained by differences in starting weight, waist circumference, age, or ethnicity.”
> “In a linear regression analysis, both men and women had a greater increase in RDI with weight gain than a decrease in RDI with weight loss.”
> “However, SDB progressed over time, even in those with stable weight.”

Source: [Newman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16287771/)

<a id="topic-2.2.1.3-3"></a>

###### All-cause and cardiovascular mortality: Wisconsin Sleep Cohort 18-year follow-up, hypopnea with 4% desaturation

> “An 18-year mortality follow-up was conducted on the population-based Wisconsin Sleep Cohort sample (n = 1522), assessed at baseline for SDB with polysomnography, the clinical diagnostic standard.”
> “Apnea was defined as cessation of airflow for ≥ 10 seconds and hypopnea was defined as a discernible reduction in breathing (sum of chest and abdominal excursions) with a reduction in oxyhemoglobin saturation of ≥ 4%.”
> “The adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 3.0 (1.4,6.3). After excluding persons who had used CPAP treatment (n = 126), the adjusted HR (95% CI) for all-cause mortality with severe versus no SDB was 3.8 (1.6,9.0); the adjusted HR (95% CI) for cardiovascular mortality was 5.2 (1.4,19.2). Results were unchanged after accounting for daytime sleepiness.”

Source: [Young et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2542952/)

<a id="topic-2.2.1.3-4"></a>

###### All-cause mortality: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation

> “We prospectively examined whether sleep-disordered breathing was associated with an increased risk of death from any cause in 6,441 men and women participating in the Sleep Heart Health Study.”
> “The apnea–hypopnea index (AHI) was defined as the number of apneas and hypopneas, each associated with a 4% or greater decrease in oxygen saturation, per hour of sleep.”
> “The average follow-up period for the cohort was 8.2 y during which 1,047 participants (587 men and 460 women) died. Compared to those without sleep-disordered breathing (AHI: <5 events/h), the fully adjusted hazard ratios for all-cause mortality in those with mild (AHI: 5.0–14.9 events/h), moderate (AHI: 15.0–29.9 events/h), and severe (AHI: ≥30.0 events/h) sleep-disordered breathing were 0.93 (95% CI: 0.80–1.08), 1.17 (95% CI: 0.97–1.42), and 1.46 (95% CI: 1.14–1.86), respectively.”
> “Stratified analyses by sex and age showed that the increased risk of death associated with severe sleep-disordered breathing was statistically significant in men aged 40–70 y (hazard ratio: 2.09; 95% CI: 1.31–3.33). Measures of sleep-related intermittent hypoxemia, but not sleep fragmentation, were independently associated with all-cause mortality.”

Source: [Punjabi et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2722083/)

<a id="topic-2.2.1.3-5"></a>

###### All-cause mortality: Busselton Health Study, home-monitor respiratory disturbance index with 3% desaturation

> “Residents of the Western Australian town of Busselton underwent investigation with a home sleep apnea monitoring device (MESAM IV). OSA was quantified via the respiratory disturbance index (RDI).”
> “Respiratory disturbances were defined as oxygen desaturations of ≥ 3% from the preceding baseline level that were accompanied by either a) an increased heart rate ≥ 10 beats/min and/or b) a burst of snoring associated with commencement and termination of the desaturation event (i.e., an audible apnea).”
> “Among the 380 participants, 18 had moderate-severe OSA (RDI ≥15/hr, 6 deaths) and 77 had mild OSA (RDI 5 to <15/hr, 5 deaths). Moderate-to-severe OSA was independently associated with greater risk of all-cause mortality (fully adjusted hazard ratio [HR] = 6.24, 95% CL 2.01, 19.39) than non-OSA (n = 285, 22 deaths). Mild OSA (RDI 5 to <15/hr) was not an independent risk factor for higher mortality (HR = 0.47, 95% CL 0.17, 1.29).”

Source: [Marshall et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2542953/)

<a id="topic-2.2.1.3-6"></a>

###### Fatal and non-fatal cardiovascular events: untreated severe disease and CPAP-treated men in a sleep clinic cohort

> “Participants were followed-up at least once per year for a mean of 10.1 years (SD 1.6) and CPAP compliance was checked with the built-in meter.”
> “Patients with untreated severe disease had a higher incidence of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) than did untreated patients with mild-moderate disease (0.55, p=0.02 and 0.89, p<0.0001), simple snorers (0.34, p=0.0006 and 0.58, p<0.0001), patients treated with CPAP (0.35, p=0.0008 and 0.64, p<0.0001), and healthy participants (0.3, p=0.0012 and 0.45, p<0.0001).”
> “Multivariate analysis, adjusted for potential confounders, showed that untreated severe obstructive sleep apnoea-hypopnoea significantly increased the risk of fatal (odds ratio 2.87, 95%CI 1.17-7.51) and non-fatal (3.17, 1.12-7.51) cardiovascular events compared with healthy participants.”

Source: [Marin et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15781100/)

<a id="topic-2.2.1.3-7"></a>

###### Cardiovascular mortality by hypoxic burden: MrOS and Sleep Heart Health Study

> “The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline.”
> “Unlike the AHI, the hypoxic burden strongly predicted CVD mortality and all-cause mortality (only in MrOS). Individuals in the MrOS study with hypoxic burden in the highest two quintiles had hazard ratios of 1.81 [95% confidence interval (CI) 1.25–2.62] and 2.73 (95% CI 1.71–4.36), respectively. Similarly, the group in the SHHS with hypoxic burden in the highest quintile had a hazard ratio of 1.96 (95% CI 1.11–3.43).”

Source: [Azarbarzin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451769/)

<a id="topic-2.2.1.3-8"></a>

###### Long-term outcomes of untreated disease: systematic review of longitudinal studies

> “Among 26 articles, ten evaluated the association of OSA with mortality, 9 with a composite CV outcome, 4 with stroke, 2 with diabetes and 1 with depression. Significant relationships between the apnea-hypopnea index (AHI) and outcomes of interest were reported in 18 studies: seven for all-cause mortality, six for composite CV events, three for stroke, one for diabetes and one for depression. The effect of AHI was attenuated by female gender, older age, absence of daytime sleepiness and higher body mass index.”
> “Evidence exists in men for a relationship between OSA and all-cause mortality and a composite CV outcome. Associations between OSA and other outcomes remain uncertain.”

Source: [Kendzerska et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/23642349/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Upper airway collapse when anatomical collapsing forces exceed dilator muscle compensation

> “This will occur if the anatomical structures within or surrounding the airway produce a collapsing force that cannot be adequately compensated for by pharyngeal dilator muscles.”

Source: [Wellman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3119134/)

<a id="topic-2.2.1.4-2"></a>

###### Endotype framework: four physiological traits that cause OSA

> “In this study, we present a noninvasive method for measuring four important physiological traits causing OSA: 1) pharyngeal anatomy/collapsibility, 2) ventilatory control system gain (loop gain), 3) the ability of the upper airway to dilate/stiffen in response to an increase in ventilatory drive, and 4) arousal threshold.”
> “The measurements and model illustrate the multifactorial nature of OSA pathogenesis and how, in some individuals, small adjustments of one or another trait (which might be achievable with non-CPAP agents) could potentially treat OSA.”

Source: [Wellman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3119134/)

<a id="topic-2.2.1.4-3"></a>

###### Endotype framework: distribution of anatomical and nonanatomical traits among patients with OSA

> “A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain.”
> “A total of 28% had multiple nonanatomic features.”
> “One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.”
> “This study confirms that OSA is a heterogeneous disorder.”

Source: [Eckert et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3826282/)

<a id="topic-2.2.1.4-4"></a>

###### Endotype framework: impaired anatomy and the three nonanatomical phenotypes

> “Indeed, impairment in pharyngeal anatomy can be modest and in many patients (∼20%), pharyngeal collapsibility asleep is not different to people without OSA.”
> “These include impairment in pharyngeal dilator muscle control and function during sleep, increased propensity for awakening during airway narrowing (low respiratory arousal threshold) and respiratory control instability (high loop gain).”
> “Each phenotype is a potential therapeutic target.”

Source: [Eckert (2018)](https://pubmed.ncbi.nlm.nih.gov/28110857/)

<a id="topic-2.2.1.4-5"></a>

###### Endotype framework: estimating collapsibility and muscle compensation from diagnostic polysomnography

> “Here we aimed to provide a means to quantify two key contributors to OSA—pharyngeal collapsibility and compensatory muscle responsiveness—that is applicable to diagnostic polysomnography.”
> “Phenotypes of pharyngeal dysfunction in OSA are evident from spontaneous changes in ventilation and ventilatory drive during sleep, enabling noninvasive phenotyping in the clinic.”

Source: [Sands et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6019932/)

<a id="topic-2.2.1.4-6"></a>

###### Pharyngeal dilator muscle control: noradrenergic withdrawal in NREM sleep and muscarinic inhibition in REM sleep

> “Some preclinical works identified the main cause of sleep-related hypotonia of the pharyngeal muscles to be the central reduction of norepinephrine from wakefulness to sleep.”
> “In addition, an inhibitory effect of acetylcholine through muscarinic receptors was found to be responsible for the REM-related hypotonia.”
> “Two key contributors are now thought to be important: sleep-related withdrawal of endogenous noradrenergic drive is a major cause of genioglossus hypotonia, particularly during non-REM (NREM) sleep (16), and active muscarinic inhibition mediates pharyngeal hypotonia, particularly during REM (17).”

Source: [Taranto-Montemurro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6519859/)

<a id="topic-2.2.1.4-7"></a>

###### Pharyngeal dilator muscle control: muscarinic and GIRK channel inhibition at the hypoglossal motor pool in REM sleep (rat study)

> “Here we show that muscarinic receptor antagonism at the hypoglossal motor pool prevents the inhibition of genioglossus activity throughout REM sleep; likewise, with G-protein-coupled inwardly rectifying potassium (GIRK) channel blockade.”
> “This mechanism is the major cause of REM sleep inhibition at a pharyngeal motor pool critical for effective breathing.”

Source: [Grace et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23220910/)

<a id="topic-2.2.1.4-8"></a>

###### Pharyngeal dilator muscle control: genioglossus motor unit activity during REM sleep in humans

> “Overall these data show diminished genioglossus activity during REM (particularly phasic REM) as evidenced by fewer SMUs being active, reduced discharge frequencies, and shorter firing durations.”
> “Neither the source of this cholinergic input nor the nature of interactions between cholinergic, noradrenergic, and other excitatory neurochemicals is understood.”

Source: [McSharry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3920322/)

<a id="topic-2.2.1.4-9"></a>

###### Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)

> “While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.”
> “Nonanatomical causes contribute to OSA in approximately 70% of patients.”
> “This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.”
> “Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.”
> “AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.”
> “R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.”
> “L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic criteria: ICSD-3-TR as reproduced in the VA/DoD guideline

> “Diagnostic Criteria ((A and B) or C) + D must be met A. The presence of one or more of the following: 1. The patient complains of sleepiness, fatigue, insomnia, or other symptoms leading to impaired sleep-related quality of life. 2. The patient wakes with breath holding, gasping, or choking 3. The bed partner or other observer reports habitual snoring or breathing interruptions during the patient's sleep B. PSG or HSAT demonstrates: 1. Five or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT) C. PSG or HSAT demonstrates: 1. Fifteen or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT) D. The symptoms are not better explained by another current sleep disorder, medical disorder, medication or substance use.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-2"></a>

###### Diagnostic criteria: ICSD-3 definition as stated in the AASM diagnostic testing guideline

> “The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).”
> “In addition to apneas and hypopneas that are included in the AHI, the RDI includes respiratory effort-related arousals (RERAs).”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-3"></a>

###### Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing

> “Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation.”
> “We recommend that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (STRONG)”
> “We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)”
> “We recommend that if a single home sleep apnea test is negative, inconclusive, or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)”
> “We recommend that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (STRONG)”
> “We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used for the diagnosis of OSA. (WEAK)”
> “We suggest that when the initial polysomnogram is negative and clinical suspicion for OSA remains, a second polysomnogram be considered for the diagnosis of OSA. (WEAK)”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-4"></a>

###### Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index

> “An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.”
> “A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT with oximetry and actigraphy.”
> “A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.”
> “Measurement error is inevitable in HSAT, compared against PSG, as standard sleep staging channels are not typically monitored in HSAT (e.g., EEG, EOG and EMG monitoring are not typically performed), which results in use of the recording time rather than sleep time to define the denominator of the respiratory event index (REI; the term used to represent the frequency of apneas and hypopneas derived from HSAT).”
> “HSAT devices that use conventional sensors are unable to detect hypopneas only associated with cortical arousals, which are included in the recommended AHI scoring rule in the AASM Scoring Manual.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-5"></a>

###### Screening and diagnostic testing: VA/DoD 2025 Recommendations 1 to 4

> “1. For screening of patients with sleep complaints, we suggest using validated screening instruments for both insomnia (e.g., Insomnia Severity Index or Athens Insomnia Scale) and obstructive sleep apnea (e.g., STOP) to identify patients who need further evaluation. Weak for Not reviewed, Amended”
> “2. For diagnosis of clinically suspected obstructive sleep apnea, we recommend diagnosis with polysomnography or home sleep apnea testing. Strong for Reviewed, New-added”
> “3. For diagnosis of obstructive sleep apnea in appropriate patients*, we suggest home sleep apnea testing as an alternative to in-laboratory polysomnography. Weak for Reviewed, New- replaced”
> “4. For diagnosis of patients with a non-diagnostic home sleep apnea test, we recommend further sleep testing for obstructive sleep apnea with in-lab polysomnography or HSAT. Strong for Reviewed, New- replaced”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-6"></a>

###### Screening: STOP questionnaire scoring in the VA/DoD guideline

> “High risk of OSA: answering yes to two or more questions Low risk of OSA: answering yes to less than two questions”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-7"></a>

###### Severity thresholds: VA/DoD 2025 guideline, AHI on HSAT and severity for treatment selection

> “Sidebar 8. AHI 5 to <15 on HSAT 1. Treatment for OSA is recommended for symptomatic patients with an AHI or REI of 5 to <15 events per hour 2. For patients who will have limitations to their work and/or lifestyle, definitive testing with an in-lab PSG is recommended 3. For the general population without such restrictions, an AHI of 5 to <15 events per hour on HSAT should be treated as OSA”
> “1. Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour) 2. Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-8"></a>

###### Severity thresholds: AASM 2009 adult OSA clinical guideline

> “The diagnosis of OSA is confirmed if the number of obstructive events (apneas, hypopneas + respiratory event related arousals) on PSG is greater than 15 events/hr or greater than 5/hour in a patient who reports any of the following: unintentional sleep episodes during wakefulness; daytime sleepiness; unrefreshing sleep; fatigue; insomnia; waking up breath holding, gasping, or choking; or the bed partner describing loud snoring, breathing interruptions, or both during the patient's sleep.”
> “OSA severity is defined as mild for RDI ≥ 5 and < 15, moderate for RDI ≥ 15 and ≤ 30, and severe for RDI > 30/hr (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.5-9"></a>

###### Severity thresholds: 1999 AASM task force grades and their consensus basis

> “They also recommended severity criteria based on degree of sleepiness and frequency of respiratory events, with the following severity grades based on the number of obstructive breathing events per hour:”
> “Mild: 5 to 15 events per hour”
> “Moderate: >15 to 30 events per hour”
> “Severe: greater than 30 events per hour”
> “It should be noted that these recommendations were based on expert consensus, with an acknowledgment that the data on which to base these event definitions and severity measures were limited.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-2.2.1.5-10"></a>

###### Scoring rules: AASM 2012 recommended hypopnea rule with 3% desaturation or arousal, and 4% rule for reimbursement

> “Score a respiratory event as a hypopnea if all of the following are met:”
> “The peak signal excursions drop by ≥ 30% of pre-event baseline using nasal pressure (diagnostic study), PAP device flow (titration study), or an alternative hypopnea sensor.”
> “The duration of the ≥ 30% drop in signal excursions is ≥ 10 seconds.”
> “There is ≥ 3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.”
> “Note: If necessary, the number of hypopneas using a definition requiring ≥ 30% drop in flow for ≥ 10 seconds that is associated with ≥ 4% desaturation may additionally be reported to qualify a patient for PAP reimbursement (e.g., Medicaid or Medicare patients).”
> “For Medicaid and Medicare patients the use of a hypopnea definition based on a 30% drop in flow and 4% or greater desaturation will need to be used to ensure reimbursement until reimbursement policies are changed to reflect the new hypopnea definition.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-11"></a>

###### Scoring rules: AASM 2012 adult apnea rule

> “Score a respiratory event in adults as an apnea if both of the following are met:”
> “There is a drop in the peak signal excursion by ≥ 90% of pre-event baseline using an oronasal thermal sensor (diagnostic study), positive airway pressure device flow (titration study), or an alternative apnea sensor.”
> “The duration of the ≥ 90% drop in sensor signal is ≥ 10 seconds.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-12"></a>

###### Effect of the hypopnea definition on the AHI: 3% versus 4% desaturation

> “Recognizing the apparent equivalence of hypopnea definitions requiring ≥ 3% or ≥ 4% desaturation, the task force has recommended adoption of the 3% criterion.”
> “with median AHI in a general community sample being almost twice as great using a 3% as a 4% criterion”
> “Therefore, thresholds for identification of the presence and severity of OSA, and for inferring health-related consequences of OSA, must be calibrated to the hypopnea definition employed.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-13"></a>

###### Effect of the hypopnea definition on the AHI: three AASM definitions in clinical polysomnography

> “For AHIRec, hypopneas were required to have ≥ 30% airflow reduction and ≥ 4% desaturation; and for AHIAlt, hypopneas were required to have ≥ 50% airflow reduction and ≥ 3% desaturation or arousal. The median AHIRec was approximately 30% of the median AHIChicago, whereas the median AHIAlt was approximately 60% of the AHIChicago, with large, AHI-dependent, patient-specific differences observed.”
> “Failure to adjust cut-points for the new criteria would result in approximately 40% of patients previously classified as positive for OSA using AHIChicago being negative using AHIRec and 25% being negative using AHIAlt.”
> “This study demonstrates that using different published standard hypopnea definitions leads to marked differences in AHI.”

Source: [Ruehland et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2635578/)

<a id="topic-2.2.1.5-14"></a>

###### Medicare coverage thresholds: CPAP national coverage determination, AHI or RDI with 4% desaturation hypopnea rule

> “Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.”
> “The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.”
> “An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criterion using the AHI or RDI are met:”
> “AHI or RDI greater than or equal to 15 events per hour, or”
> “AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.”
> “If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at a minimum the number of events that would have been required in a 2-hour period.”

Source: [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)

<a id="topic-2.2.1.5-15"></a>

###### Medicare coverage of sleep tests: national coverage determination for sleep testing

> “1. Type I PSG is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed attended in a sleep lab facility.”
> “2. Type II or Type III sleep testing devices are covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”
> “3. Type IV sleep testing devices measuring three or more channels, one of which is airflow, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”
> “4. Sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”

Source: [CMS National Coverage Determination 240.4.1 (2009)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=330)

<a id="topic-2.2.1.5-16"></a>

###### Sleepiness assessment: Epworth Sleepiness Scale

> “This is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.”
> “They rated the chances that they would doze off or fall asleep when in eight different situations commonly encountered in daily life.”
> “In patients with obstructive sleep apnea syndrome ESS scores were significantly correlated with the respiratory disturbance index and the minimum SaO2 recorded overnight.”

Source: [Johns (1991)](https://pubmed.ncbi.nlm.nih.gov/1798888/)

<a id="topic-2.2.1.5-17"></a>

###### Metrics beyond the AHI: hypoxic burden and limits of the AHI

> “Apnoea–hypopnoea index (AHI), the universal clinical metric of sleep apnoea severity, poorly predicts the adverse outcomes of sleep apnoea, potentially because the AHI, a frequency measure, does not adequately capture disease burden.”
> “The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline.”

Source: [Azarbarzin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451769/)

> “Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect. We further review the potential value of alternative metrics including hypoxic burden, arousal intensity, odds ratio product, and cardiopulmonary coupling.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Nocturnal symptoms: snoring, witnessed apneas, gasping or choking, nocturia, and morning headaches

> “A comprehensive sleep history in a patient suspected of OSA should include an evaluation for snoring, witnessed apneas, gasping/choking episodes, excessive sleepiness not explained by other factors, including assessment of sleepiness severity by the Epworth Sleepiness Scale,”
> “total sleep amount, nocturia, morning headaches, sleep fragmentation/sleep maintenance insomnia, and decreased concentration and memory (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-2"></a>

###### Daytime symptoms: unrefreshing sleep, fatigue, and sleepiness

> “Individuals with OSA often feel unrested, fatigued, and sleepy during the daytime.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.6-3"></a>

###### Daytime symptoms: sleepiness across respiratory disturbance index levels in the Sleep Heart Health Study

> “Sleep-disordered breathing was quantified by the respiratory disturbance index (RDI), defined as the number of apneas plus hypopneas per hour of sleep, measured during in-home polysomnography.”
> “When RDI was categorized into four groups (< 5, 5 to < 15, 15 to < 30, >/= 30), a significantly progressive increase in mean ESS score was seen across all four levels of SDB, from 7.2 (4.3) in subjects with RDI < 5 to 9.3 (4.9) in subjects with RDI >/= 30 (p < 0.001).”
> “The percentage of subjects with excessive sleepiness, defined as an ESS score >/= 11, increased from 21% in subjects with RDI < 5 to 35% in those with RDI >/= 30 (p < 0. 001).”

Source: [Gottlieb et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/9927364/)

<a id="topic-2.2.1.6-4"></a>

###### Neurocognitive and psychosocial symptoms: vigilance, concentration, cognition, and quality of life

> “They may suffer from impairments in vigilance, concentration, cognitive function, social interactions and quality of life (QOL). These declines in daytime function can translate into higher rates of job-related and motor vehicle accidents.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.6-5"></a>

###### Insomnia symptoms: comorbid insomnia and obstructive sleep apnea

> “Co-morbid insomnia has been found to be a frequent problem in patients with OSA.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

> “The largest prospective observational study of active-duty service members referred to a sleep center diagnosed insomnia in 32.7% of patients, OSA in 30.4%, and comorbid insomnia and obstructive sleep apnea (COMISA) in 36.9%.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.6-6"></a>

###### Physical signs: obesity, neck circumference, and upper airway anatomy

> “Particular attention should be paid to the presence of obesity, signs of upper airway narrowing, or the presence of other disorders that can contribute to the development of OSA or to the consequences of OSA.”
> “body mass index (BMI) ≥ 30 kg/m2, a Modified Mallampati score of 3 or 4”
> “the presence of retrognathia, lateral peritonsillar narrowing, macroglossia, tonsillar hypertrophy, elongated/enlarged uvula, high arched/narrow hard palate, nasal abnormalities (polyps, deviation, valve abnormalities, turbinate hypertrophy) and/or overjet (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-7"></a>

###### Cardiometabolic presentation: conditions that place patients at high risk of OSA

| High-risk group | Quoted entry |
| --- | --- |
| Obesity | “Obesity (BMI > 35)” |
| Heart failure | “Congestive heart failure” |
| Arrhythmia | “Atrial fibrillation” |
| Hypertension | “Treatment refractory hypertension” |
| Diabetes | “Type 2 diabetes” |
| Arrhythmia | “Nocturnal dysrhythmias” |
| Cerebrovascular disease | “Stroke” |
| Pulmonary vascular disease | “Pulmonary hypertension” |
| Occupational | “High-risk driving populations” |
| Surgical | “Preoperative for bariatric surgery” |

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-8"></a>

###### Symptom subtypes: disturbed sleep, minimally symptomatic, excessively sleepy, and moderately sleepy in the Sleep Heart Health Study

> “Data from 1,207 patients with OSA (apnea–hypopnea index ≥ 15 events/h) were used to evaluate the existence of symptom subtypes using latent class analysis.”
> “Four symptom subtypes were identified (disturbed sleep [12.2%], minimally symptomatic [32.6%], excessively sleepy [16.7%], and moderately sleepy [38.5%]), similar to prior studies.”

Source: [Mazzotti et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6701040/)

<a id="topic-2.2.1.6-9"></a>

###### Minimally symptomatic presentation: undiagnosed and minimally sleepy populations

> “While most of these cases are undiagnosed, it is likely that most are asymptomatic or minimally symptomatic, and it remains uncertain whether these individuals have a disorder that requires therapeutic intervention”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

> “Most of the participants were men who had moderate-to-severe obstructive sleep apnea and minimal sleepiness.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.1.6-10"></a>

###### Sex differences in symptoms: matched men and women across AHI strata

> “Study participants were classified as having no SDB (apnea-hypopnea index [AHI] <5 events/h), mild SDB (5.0-14.9 events/h), or moderate-to-severe SDB (≥15 events/h). Within each stratum, men and women were matched 1:1 on age, race, body mass index, and AHI.”
> “whereas women had more insomnia symptoms and lower physical and mental quality-of-life scores (both p = 0.001)”
> “Comparable levels of SDB severity carry different physiologic and symptomatic consequences in men and women, indicating that assessment should extend beyond AHI alone to include sleep disruption, symptom profile, and functional impact.”

Source: [Hurst et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42600422/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Hypertension: incident hypertension in the Wisconsin Sleep Cohort by baseline AHI

> “Participants were assessed overnight by 18-channel polysomnography for sleep-disordered breathing, as defined by the apnea-hypopnea index (the number of episodes of apnea and hypopnea per hour of sleep).”
> “Relative to the reference category of an apnea-hypopnea index of 0 events per hour at base line, the odds ratios for the presence of hypertension at follow-up were 1.42 (95 percent confidence interval, 1.13 to 1.78) with an apnea-hypopnea index of 0.1 to 4.9 events per hour at base line as compared with none, 2.03 (95 percent confidence interval, 1.29 to 3.17) with an apnea-hypopnea index of 5.0 to 14.9 events per hour, and 2.89 (95 percent confidence interval, 1.46 to 5.64) with an apnea-hypopnea index of 15.0 or more events per hour.”
> “We found a dose-response association between sleep-disordered breathing at base line and the presence of hypertension four years later that was independent of known confounding factors.”

Source: [Peppard et al. (2000a)](https://pubmed.ncbi.nlm.nih.gov/10805822/)

<a id="topic-2.2.1.7-2"></a>

###### Hypertension: cross-sectional association in the Sleep Heart Health Study, hypopnea with 4% desaturation

> “Apnea-hypopnea index (AHI, the average number of apneas plus hypopneas per hour of sleep, with apnea defined as a cessation of airflow and hypopnea defined as a > or = 30% reduction in airflow or thoracoabdominal excursion both of which are accompanied by a > or = 4% drop in oxyhemoglobin saturation) [corrected], obtained by unattended home polysomnography.”
> “After adjusting for demographics and anthropometric variables (including BMI, neck circumference, and waist-to-hip ratio), as well as for alcohol intake and smoking, the odds ratio for hypertension, comparing the highest category of AHI (> or = 30 per hour) with the lowest category (< 1.5 per hour), was 1.37 (95% confidence interval [CI], 1.03-1.83; P for trend = .005).”

Source: [Nieto et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10770144/)

<a id="topic-2.2.1.7-3"></a>

###### Cardiovascular disease: prevalence of OSA in cardiovascular conditions, American Heart Association statement

> “OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.”
> “We recommend screening for OSA in patients with resistant/poorly controlled hypertension, pulmonary hypertension, and recurrent atrial fibrillation after either cardioversion or ablation.”

Source: [Yeghiazarians et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34148375/)

<a id="topic-2.2.1.7-4"></a>

###### Coronary heart disease and heart failure: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation

> “where both apneas and hypopneas required an associated 4% or greater oxyhemoglobin desaturation”
> “A prospective, longitudinal epidemiologic study of 1927 men and 2495 women aged ≥ 40 years and free of coronary heart disease and heart failure at the time of baseline polysomnography were followed for a median of 8.7 years.”
> “Among men age 40–70 years, those with AHI ≥30 were 68% more likely to develop coronary heart disease than those with AHI <5. OSA predicted incident heart failure in men but not in women (adjusted hazard ratio 1.13 [95% CI 1.02, 1.26] per 10-unit increase in AHI). Men with AHI ≥30 were 58% more likely to develop heart failure than those with AHI <5.”

Source: [Gottlieb et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3117288/)

<a id="topic-2.2.1.7-5"></a>

###### Cardiovascular disease: incident events by symptom subtype in the Sleep Heart Health Study

> “Symptom subtype was also associated with incident cardiovascular disease (P < 0.001), coronary heart disease (P = 0.015), and heart failure (P = 0.018), with the excessively sleepy again demonstrating increased risk (hazard ratios, 1.7–2.4) compared with other subtypes.”

Source: [Mazzotti et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6701040/)

<a id="topic-2.2.1.7-6"></a>

###### Ischemic stroke: Sleep Heart Health Study, obstructive apnea-hypopnea index

> “A total of 5,422 participants without a history of stroke at the baseline examination and untreated for sleep apnea were followed for a median of 8.7 years. One hundred ninety-three ischemic strokes were observed.”
> “Men in the highest OAHI quartile (>19) had an adjusted hazard ratio of 2.86 (95% confidence interval, 1.1–7.4). In the mild to moderate range (OAHI, 5–25), each one-unit increase in OAHI in men was estimated to increase stroke risk by 6% (95% confidence interval, 2–10%). In women, stroke was not significantly associated with OAHI quartiles, but increased risk was observed at an OAHI greater than 25.”

Source: [Redline et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2913239/)

<a id="topic-2.2.1.7-7"></a>

###### Atrial fibrillation and other arrhythmias: Sleep Heart Health Study, respiratory disturbance index of 30 or more

> “(1) 228 subjects with sleep-disordered breathing (respiratory disturbance index ⩾ 30) and (2) 338 subjects without sleep-disordered breathing (respiratory disturbance index < 5).”
> “4.8 versus 0.9% (p = 0.003) for atrial fibrillation; 5.3 versus 1.2% (p = 0.004) for nonsustained ventricular tachycardia; 25.0 versus 14.5% (p = 0.002) for complex ventricular ectopy.”
> “individuals with sleep-disordered breathing had four times the odds of atrial fibrillation (odds ratio [OR], 4.02; 95% confidence interval [CI], 1.03–15.74), three times the odds of nonsustained ventricular tachycardia (OR, 3.40; 95% CI, 1.03–11.20), and almost twice the odds of complex ventricular ectopy (OR, 1.74; 95% CI, 1.11–2.74).”

Source: [Mehra et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2662909/)

<a id="topic-2.2.1.7-8"></a>

###### Atrial fibrillation: incident hospitalization in a Western Australian sleep clinic cohort

> “Study case subjects (6,841) were predominantly middle aged (48.3 ± 12.5 years old) and men (77%), and 455 developed AF during a median 11.9 years of follow-up.”
> “After multivariable adjustment, independent predictors of incident AF were an apnea/hypopnea index (AHI) > 5/h (hazard ratio [HR], 1.55; 95% CI, 1.21-2.00), log (AHI + 1) (HR, 1.15; 95% CI, 1.06-1.26), and log (time with oxygen saturation < 90% + 1) (HR, 1.12; 95% CI, 1.06-1.19).”

Source: [Cadby et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25927872/)

<a id="topic-2.2.1.7-9"></a>

###### Type 2 diabetes: Wisconsin Sleep Cohort, hypopnea with 4% desaturation

> “A total of 14.7% of subjects with an apnea–hypopnea index (AHI) of 15 or more had a diagnosis of diabetes compared with 2.8% of subjects with an AHI of less than 5.”
> “The odds ratio for developing diabetes mellitus within 4 yr with an AHI of 15 or more compared with an AHI of less than 5 was 1.62 (95% confidence interval, 0.67–3.65; p = 0.24) when adjusting for age, sex, and body habitus.”
> “Although all hypopnea events were marked by oxyhemoglobin desaturation of 4% or greater”

Source: [Reichmuth et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2718458/)

<a id="topic-2.2.1.7-10"></a>

###### Type 2 diabetes: meta-analysis of prospective cohort studies

> “This meta-analysis of six prospective cohort studies including a total of 5953 participants, with follow-up periods of 2.7-16 years, and 332 incident cases of type 2 diabetes, showed that moderate-severe OSA was associated with a greater risk of diabetes (RR 1.63; 95% confidence interval (CI): 1.09-2.45), as compared with the absence of OSA.”
> “For subjects with mild OSA, as compared with those without OSA, the pooled RR of developing type 2 diabetes was 1.22 (95% CI: 0.91-1.63).”

Source: [Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22988888/)

<a id="topic-2.2.1.7-11"></a>

###### Motor vehicle crashes: systematic review and meta-analysis of crash risk

> “Individuals with OSA are clearly at increased risk for crash. The mean crash-rate ratio associated with OSA is likely to fall within the range of 1.21 to 4.89. Characteristics that may predict crash in drivers with OSA include BMI, apnea plus hypopnea index, oxygen saturation, and possibly daytime sleepiness.”

Source: [Tregear et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792976/)

<a id="topic-2.2.1.7-12"></a>

###### Cognitive impairment: mild cognitive impairment or dementia in older women, AHI of 15 or more

> “Sleep disordered breathing was defined as an apnea-hypopnea index of 15 or more events per hour of sleep.”
> “Compared with the 193 women without sleep disordered breathing, the 105 women (35.2%) with SDB were more likely to develop MCI/dementia (n=60 (31.1%) vs n=47 (44.8%)) even after multivariate adjustment (adjusted OR=1.85, 95% CI 1.11-3.08).”

Source: [Yaffe et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3600944/)

<a id="topic-2.2.1.7-13"></a>

###### Cognitive impairment: meta-analysis of population-based studies

> “Pooled analysis of the 6 prospective studies indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment, with no evidence of publication bias but significant heterogeneity between studies.”
> “Sleep-disordered breathing was not associated with global cognition or memory.”

Source: [Leng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710301/)

<a id="topic-2.2.1.7-14"></a>

###### Cognitive decline: untreated and CPAP-treated older adults with Medicare claims for OSA

> “We analyzed 777 participants from the 2011 National Health and Aging Trends Study (NHATS) with linked Medicare claims, with one or more claims for OSA and no baseline cognitive impairment.”
> “Untreated participants experienced a 69% faster decline”

Source: [Kaufmann et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13366499/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Obstructive sleep apnea

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### SF-36 quality of life by sleep-disordered breathing severity in the Sleep Heart Health Study

> “Participants (n=5,816; mean age=63 years; 52.5% women) were enrolled in the nation-wide population-based Sleep Heart Health Study (SHHS) implemented to investigate sleep-disordered breathing as a risk factor in the development of cardiovascular disease.”
> “Vitality was the sole SF-36 scale to have a linear association with the clinical categories of SDB (mild, moderate, severe SDB). However, individuals with severe SDB indicated significantly poorer QoL on several SF-36 scales.”
> “Findings suggest 1) mild to moderate SDB is associated with reduced vitality, while severe SDB is more broadly associated with poorer QoL, 2) subjective sleep symptoms are comprehensively associated with poorer QoL, and 3) SF-36 mean score profiles for SDB and sleep symptoms are equivalent to other chronic diseases in the U.S. general population.”

Source: [Baldwin et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11204058/)

<a id="topic-2.2.1.8.1-2"></a>

###### Health-related quality of life, utility, and work productivity with and without excessive sleepiness in the US National Health and Wellness Survey

> “Respondents self-reporting an OSA diagnosis were categorized as having ES (Epworth Sleepiness Scale [ESS] score ≥ 11) or not having ES (ESS score < 11). Comorbidities, health-related quality of life (HRQoL), and productivity were examined in three groups: OSA with ES (n = 731), OSA without ES (n = 1,452), and non-OSA controls (n = 86,961).”
> “After controlling for covariates, the OSA with ES group had significantly lower (worse) scores for mental component score (41.81 versus 45.65 versus 47.81), physical component score (46.62 versus 48.68 versus 51.36), and SF-6D (0.65 versus 0.69 versus 0.73) compared with OSA without ES and non-OSA controls (all P < .001).”
> “The OSA with ES group had significantly higher (greater burden) mean rates of presenteeism (25.98% impairment versus 19.24% versus 14.75%), work impairment (29.41% versus 21.82% versus 16.85%), and activity impairment (31.09% versus 25.46% versus 19.93%) compared with OSA without ES and non-OSA controls (all P < .01) after controlling for covariates.”

Source: [Stepnowsky et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374092/)

<a id="topic-2.2.1.8.1-3"></a>

###### Health state utilities by AHI severity in adults with obstructive sleep apnea and obesity, time trade-off study

> “Participants with OSA and obesity (BMI ≥ 30) in the UK and US valued health state vignettes in time trade-off interviews.”
> “Vignettes described four levels of OSA severity defined by apnea-hypopnea index: remission (<5), mild (5-14.9), moderate (15-29.9), and severe (≥30).”
> “A total of 208 participants (UK = 105; US = 103) completed interviews (50.0% male; mean age = 53.6y). Mean (SD) utilities ranged from 0.93 (0.08) for mild OSA to 0.85 (0.15) for severe OSA when considering health states with the option to use non-pharmacologic treatment. When participants imagined living with the symptoms of OSA without the non-pharmacologic treatment option, mean utilities ranged from 0.89 (0.13) for mild OSA to 0.68 (0.27) for severe OSA.”

Source: [Stewart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41089051/)

<a id="topic-2.2.1.8.1-4"></a>

###### Bed partner effects: sleep, daytime functioning, and relationship quality

> “The majority of studies found untreated OSA to have a negative impact on partners' objective and subjective sleep and daytime functioning, in particular mood, quality of life, and relationship quality. Improvements in partner-assessed sleep quality were reported for CPAP, OA, and surgery. Conflicting results were reported for partners' mood, quality of life, daytime sleepiness, and relationship quality. Perceived partner support was associated with greater CPAP use.”
> “For some couples, patients' snoring and its interference with partners' sleep lead to sleeping in separate rooms.”

Source: [Luyster et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337594/)

<a id="topic-2.2.1.8.1-5"></a>

###### Bed partner effects: quality of life of bed partners before and after patient CPAP treatment

> “Of the 54 subjects who completed the study, the mean (+/- SD) apnea-hypopnea index was 48.4 +/- 33.3.”
> “For the bed partners, the mean ESS decreased from 7.4 +/- 6.1 to 5.8 +/- 4.7 (p = 0.02).”
> “OSA results in impaired QOL in both the patients and their bed partners. Treatment with CPAP improves QOL, as measured by the SF-36 and the SAQLI.”

Source: [Parish and Lyng (2003)](https://pubmed.ncbi.nlm.nih.gov/12970021/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Estimated U.S. societal cost of undiagnosed obstructive sleep apnea in 2015

> “Frost & Sullivan estimates that undiagnosed OSA cost the United States approximately $149.6 billion in 2015.”
> “When calculating the respective costs for leaving OSA undiagnosed versus diagnosing and treating it, financial modeling indicates that treatment costs are approximately 33% of non-treatment costs”
> “Frost & Sullivan estimates that untreated OSA in the United States resulted in a loss of productivity estimated at $86.9 billion in 2015.”
> “The total economic impact of all motor vehicle accidents in the United States where undiagnosed OSA was a contributing factor was estimated at $26.2 billion in 2015.”
> “Costs for these accidents due to undiagnosed and untreated OSA totaled $6.5 billion in 2015.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.8.2-2"></a>

###### Workplace productivity loss attributed to obstructive sleep apnoea syndrome in the USA

> “This study estimates the prevalence and workplace productivity burden of obstructive sleep apnoea (OSA) syndrome in the UK and USA, using self-reported breathing pauses and excessive daytime sleepiness as a proxy.”
> “Annual productivity losses were estimated at US$180.2 billion in the USA and £4.22 billion in the UK. In the UK and USA, individual-level productivity losses exceeded the cost of continuous positive airway pressure (CPAP) treatment”

Source: [Rehman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41735061/)

<a id="topic-2.2.1.8.2-3"></a>

###### Medicare beneficiaries: health care use and costs in the year before obstructive sleep apnea treatment

> “The final sample (n = 287,191) included 10,317 beneficiaries with OSA and 276,874 control patients. In fully adjusted models, during the year prior to OSA diagnosis and relative to matched control patients, beneficiaries with OSA demonstrated increased HCU and higher mean total annual costs ($19,566, 95% confidence interval [CI] $13,239, $25,894) as well as higher mean annual costs across all individual points of service.”
> “Inpatient care was associated with the highest incremental costs (ie, greater than control patients; $15,482, 95% CI $8,521, $22,443) and prescriptions were associated with the lowest incremental costs (ie, greater than control patients; $431, 95% CI $339, $522).”

Source: [Wickwire et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7053009/)

<a id="topic-2.2.1.8.2-4"></a>

###### Medical costs in the year before diagnosis of sleep apnea, single health plan

> “Among cases, mean annual medical cost prior to diagnosis was $2720 versus $1384 for age and gender matched controls (p<0.01).”
> “Using available data on the prevalence of undiagnosed moderate to severe sleep apnea in middle-aged adults, we estimate that untreated sleep apnea may cause $3.4 billion in additional medical costs in the U.S.”

Source: [Kapur et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10505820/)

<a id="topic-2.2.1.8.2-5"></a>

###### Positive airway pressure adherence and health care use and costs in obstructive sleep apnea with obesity, ResMed-funded claims analysis

> “Among 173,691 patients, 35.2% were adherent, 39.1% intermediately adherent, and 25.7% nonadherent. After applying inverse probability of treatment weighting (IPTW), in year 1 post-index, adherent patients had significantly fewer ER visits and hospitalizations (0.55 ± 1.77 and 0.10 ± 0.44) compared to nonadherent patients (0.69 ± 1.78 and 0.14 ± 0.56; P < 0.001), and significantly lower total healthcare costs (11,332 ± 21,160 vs 11,927 ± 20,212; P < 0.001).”
> “This study was funded by Resmed.”

Source: [Sert Kuniyoshi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13056527/)

<a id="topic-2.2.1.8.2-6"></a>

###### Positive airway pressure adherence and health care use in comorbid insomnia and obstructive sleep apnea, ResMed-funded claims analysis

> “From a sample of 27,071 patients with COMISA (average age, 53.6 years; 53% female), 72% were at least intermediately adherent to PAP over 2 years.”
> “When viewed in the context of patients with OSA without insomnia, patients with COMISA showed lower PAP use and higher rates of resource use both before and after the index date, but showed similar relative reductions in ER visits and hospitalizations with PAP adherence.”
> “This study was funded by ResMed.”

Source: [Cole et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12720397/)

<a id="topic-2.2.1.8.2-7"></a>

###### CPAP adherence and inpatient use in Medicare beneficiaries with cardiovascular disease

> “After adjusting for covariates and relative to low adherers, high adherers demonstrated reduced inpatient visits (hazard ratio 0.75; 95% confidence interval 0.57, 0.97).”

Source: [Wickwire et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8807906/)

<a id="topic-2.2.1.8.2-8"></a>

###### CPAP adherence and 30-day readmission in Medicare beneficiaries with cardiovascular disease

> “Among 1,301 beneficiaries meeting study criteria, the 30-day readmission rate was 10.2%. In adjusted models and compared to patients with low CPAP adherence, those with high adherence had lower odds of 30-day readmission (odds ratio 0.41; 95% confidence interval 0.24–0.70).”

Source: [Bailey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713924/)

<a id="topic-2.2.1.8.2-9"></a>

###### CPAP termination and permanent work disability in the French national claims database

> “The analysis included 174,270 individuals (median age, 52.0 yr [interquartile range, 44.0–57.0 yr]; 67.5% male). The 1-year CPAP therapy termination rate was 22.3%.”
> “In an adjusted multivariable Cox model, CPAP termination was associated with an increased risk of permanent work disability (hazard ratio, 1.21; 95% confidence interval [CI], 1.04–1.41; P = 0.01), primarily in the subgroup aged >55 years (hazard ratio, 1.41; 95% CI, 1.06–1.87; P = 0.02).”

Source: [Bailly et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039934/)

<a id="topic-2.2.1.8.2-10"></a>

###### Societal cost-of-illness estimate for Italy from a systematic review

> “Twenty-six clinical (e.g., diabetes) and non-clinical (e.g., car accidents) conditions were found to be significantly influenced by OSA, contributing to an economic burden ranging from €10.7 to €32.0 billion/year in Italy. The cost of impaired quality of life due to OSA undertreatment is between €2.8 and €9.0 billion/year. These costs are substantially higher than those currently borne to diagnose and treat OSA (€234 million/year).”

Source: [Borsoi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9122203/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Obstructive sleep apnea on Families

Not applicable.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Medicare diagnostic testing requirement for CPAP coverage

> “The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.”
> “A positive diagnosis of OSA for the coverage of CPAP must include a clinical evaluation and a positive:”

Source: [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)

<a id="topic-2.2.1.8.4-2"></a>

###### Sleep test documentation required for prior authorization of tirzepatide for obstructive sleep apnea

> “The patient has an established diagnosis of moderate to severe OSA with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device.”

Source: [Aetna Zepbound prior authorization policy (2026)](https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound%20PA%20with%20Limit%206192-C%2008-2026%20v3.html)

<a id="topic-2.2.1.8.4-3"></a>

###### Share of U.S. diagnosis and treatment spending attributed to testing and office visits, 2015

> “Frost & Sullivan estimates that the cost for diagnosing and treating OSA in the United States in 2015 was approximately $12.4 billion. Approximately 7% of these costs are from physician office visits and testing which are necessary for diagnosis and ongoing management.”
> “costs average $2,105 per year for testing, appointments, treatment devices and surgery if necessary.”
> “Diagnosis can involve multiple referral appointments and an overnight sleep test, which can be difficult for some individuals. Home sleep apnea testing, although less expensive and more convenient, lacks the sensitivity to rule out a sleep apnea diagnosis because it does not generally record sleep and wakefulness.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.8.4-4"></a>

###### Home versus laboratory diagnostic pathway: payer and provider costs in the HomePAP trial

> “From the payer perspective, per subject costs for the laboratory-based pathway were $1,840 (95% confidence interval [CI] $1,660, $2,015) compared to $1,575 (95% CI $1,439, $1,716) for the home-based pathway under the base case. Costs were $264 (95% CI $39, $496, P = 0.02) in favor of the home arm.”
> “For payers, a home-based diagnostic pathway for obstructive sleep apnea with robust patient support incurs fewer costs than a laboratory-based pathway. For providers, costs are comparable if not higher, resulting in a negative operating margin.”

Source: [Kim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481018/)

<a id="topic-2.2.1.8.4-5"></a>

###### Home versus laboratory diagnostic pathway: clinical outcomes in the HomePAP trial

> “A home-based strategy for diagnosis and treatment compared with in-laboratory PSG was not inferior in terms of acceptance, adherence, time to treatment, and functional improvements.”

Source: [Rosen et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3353048/)

<a id="topic-2.2.1.8.4-6"></a>

###### Home versus laboratory diagnostic pathway: functional outcome in veterans

> “Functional outcome and treatment adherence in patients evaluated according to a home testing algorithm is not clinically inferior to that in patients receiving standard in-laboratory polysomnography.”

Source: [Kuna et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21471093/)

<a id="topic-2.2.1.8.4-7"></a>

###### Cost-effectiveness of diagnostic strategies with CPAP in a U.S. lifetime model

> “Over the lifetime horizon in a population with 50% prevalence of OSA, full-night polysomnography in conjunction with CPAP therapy is the most economically efficient strategy at any willingness-to-pay greater than $17,131 per-QALY gained because it dominates all other strategies in comparative analysis.”

Source: [Pietzsch et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3098944/)

<a id="topic-2.2.1.8.4-8"></a>

###### Cost-utility of polysomnography, home testing, and empirical CPAP

> “The incremental charges for polysomnography over home study or no testing were about $13,400 and $9200, respectively, per quality-adjusted life-year gained during this period.”

Source: [Chervin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10075617/)

<a id="topic-2.2.1.8.4-9"></a>

###### Systematic review of economic evaluations of diagnostic strategies

> “Twenty-nine studies were included. Fifteen studies included an economic evaluation alongside a clinical trial and 14 studies were model-based economic analyses.”
> “Substantial methodological heterogeneity was identified across studies, including variation in diagnostic thresholds and scoring criteria used, model structures and assumptions regarding treatment adherence.”

Source: [Osman et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721662/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Positive Airway Pressure Therapy

<a id="topic-2.2.2.1.1-1"></a>

###### VA/DoD guideline: evidence cutoff date for the 2025 recommendations

> “This CPG is based on published clinical evidence and related information available through March 31, 2024.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### VA/DoD guideline: mandibular advancement devices, PAP, or surgical referral (strong for)

> “17. For treatment of obstructive sleep apnea, we recommend one or more of the following evidence-based therapies, depending on patient values and characteristics:”
> “Thus, based on the recognized risk of catastrophic harms from not providing effective treatment for OSA, the Work Group decided upon a Strong for recommendation.”
> “Positive airway pressure (PAP) therapy in the form of auto-PAP (APAP), continuous PAP (CPAP) and bilevel PAP (BPAP) is considered the first line of therapy.”
> “The updated guideline strongly recommends treatment for OSA but does not limit the therapy to PAP.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### VA/DoD guideline algorithm: PAP as first-line therapy for severe OSA

> “Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour)”
> “Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### VA/DoD guideline: auto-titrating over fixed CPAP at initiation (weak for)

> “19. For treatment of newly diagnosed obstructive sleep apnea, we suggest initiating auto-titrating over fixed continuous positive airway pressure to facilitate usage. Weak for”
> “Although usage (hours/night) was increased with APAP, there was no significant difference observed in the number of patients adhering ≥4 hours/night between APAP and fixed CPAP.”
> “The Work Group’s confidence in the quality of the evidence for this recommendation is low.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-5"></a>

###### VA/DoD guideline: educational, behavioral, and supportive interventions to improve PAP usage (weak for)

> “26. For treatment of obstructive sleep apnea in patients who are prescribed positive airway pressure therapy, we suggest the use of in-person or telehealth educational, behavioral, and supportive interventions to improve PAP usage. Weak for”
> “Behavioral interventions showed the most significance in hourly usage with an increase in average PAP usage per night by 1.31 hours per night (95% CI: 0.95 to 1.66) when compared to usual care.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-6"></a>

###### VA/DoD guideline: PAP effects on symptoms, cardiovascular outcomes, and side effects

> “As a measure of mean disease alleviation, the studies showed that CPAP use significantly reduced OSA symptoms including snoring, witnessed apnea, choking during sleep, excessive daytime sleepiness as measured by ESS, anxiety, depression, insomnia, and functionality.”
> “The recent evidence did not show improvement in cardiovascular outcomes (CV mortality, stroke, MI, incident atrial fibrillation, and composite CV outcomes), and neurocognitive tests.”
> “As far as side effects, PAP has been associated with nasal congestion, oronasal dryness, mask discomfort, and nocturnal awakenings.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)

> “Recommendation 1: We recommend that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with excessive sleepiness. (STRONG)”
> “The TF identified 38 randomized controlled trials (RCTs) that assessed the efficacy of PAP to reduce excessive sleepiness.”
> “Recommendation 2: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with impaired sleep-related quality of life. (CONDITIONAL)”
> “Recommendation 3: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with comorbid hypertension. (CONDITIONAL)”
> “This clinical practice guideline reflects the state of knowledge at the time of publication and will be reviewed and updated as new information becomes available.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-8"></a>

###### AASM guideline: PAP initiation, modality, and adherence interventions

> “Recommendation 4: We recommend positive airway pressure therapy be initiated using either APAP at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities. (STRONG)”
> “Recommendation 5: We recommend that clinicians use either APAP or CPAP for ongoing treatment of OSA in adults. (STRONG)”
> “Recommendation 6: We suggest that clinicians use CPAP or APAP over BPAP in the routine treatment of OSA in adults. (CONDITIONAL)”
> “Recommendation 7: We recommend that educational interventions be given prior to initiation of PAP therapy in adults with OSA. (STRONG)”
> “Recommendation 9: We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-9"></a>

###### AASM guideline: no recommendation on PAP to reduce cardiovascular events in non-sleepy adults

> “There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.”
> “Meta-analyses of observational studies suggested a reduction in CV events and mortality with PAP therapy. In contrast, meta-analyses of randomized controlled trials demonstrated no clinically significant improvements in CV events or mortality.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.1-10"></a>

###### ACP guideline: CPAP as initial therapy (strong recommendation, moderate-quality evidence)

> “This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews.”
> “RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence)”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.1-11"></a>

###### SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12

> “The diagnosis of moderate-to-severe obstructive sleep apnea, which was defined as an oxygen desaturation index (the number of times per hour during the oximetry recording that the blood oxygen saturation level drops by ≥4 percentage points from baseline) of at least 12, was established with the use of a home sleep-study screening device (ApneaLink, ResMed) and was confirmed by review of the data at a central core sleep laboratory.”
> “In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.”
> “After a mean follow-up of 3.7 years, a primary end-point event had occurred in 229 participants in the CPAP group (17.0%) and in 207 participants in the usual-care group (15.4%) (hazard ratio with CPAP, 1.10; 95% confidence interval, 0.91 to 1.32; P=0.34).”
> “CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood.”
> “Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.2.1.1-12"></a>

###### ISAACC: CPAP and cardiovascular events after acute coronary syndrome in non-sleepy participants

> “The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up.”
> “Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73).”
> “Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.”

Source: [Sánchez-de-la-Torre et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31839558/)

<a id="topic-2.2.2.1.1-13"></a>

###### RICCADSA: CPAP in coronary artery disease with non-sleepy OSA, AHI of at least 15 per hour, hypopnea scoring rule not stated in the abstract

> “Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index ≥15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titrating CPAP (n = 122) or no positive airway pressure (n = 122).”
> “The incidence of the primary endpoint did not differ significantly in patients who did versus did not receive CPAP (18.1% vs. 22.1%; hazard ratio, 0.80; 95% confidence interval, 0.46-1.41; P = 0.449).”
> “Adjusted on-treatment analysis showed a significant cardiovascular risk reduction in those who used CPAP for ≥4 versus <4 hours per night or did not receive treatment (hazard ratio, 0.29; 95% confidence interval, 0.10-0.86; P = 0.026).”

Source: [Peker et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26914592/)

<a id="topic-2.2.2.1.1-14"></a>

###### CPAP and incident hypertension or cardiovascular events in non-sleepy OSA, AHI of at least 20 per hour, hypopnea scoring rule not stated in the abstract

> “Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an apnea-hypopnea index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values <10 suggesting no daytime sleepiness).”
> “The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P = .20).”
> “In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of hypertension or cardiovascular events. However, the study may have had limited power to detect a significant difference.”

Source: [Barbé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22618923/)

<a id="topic-2.2.2.1.1-15"></a>

###### Individual participant data meta-analysis of SAVE, ISAACC, and RICCADSA: intention-to-treat and adherent CPAP use

> “The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).”
> “A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years).”

Source: [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/)

<a id="topic-2.2.2.1.1-16"></a>

###### Meta-analysis of randomized trials: PAP and cardiovascular events or death in sleep apnea

> “The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.”
> “Mean or median adherence to the intervention ranged between 1.4 hours per day and 6.6 hours per day.”

Source: [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/)

<a id="topic-2.2.2.1.1-17"></a>

###### Adherence: nonadherence range across studies using a 4-hour nightly threshold

> “When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to treatment.”

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/)

<a id="topic-2.2.2.1.1-18"></a>

###### Adherence: CPAP nonadherence pooled across 20 years of trials, relative to a 7-hour night

> “The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.1.1-19"></a>

###### Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database

> “We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.”
> “All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.”
> “ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.”
> “The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).”
> “The observed 90-day PAP adherence rate using the CMS definition was 75%.”
> “Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.”

Source: [Cistulli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6589354/)

<a id="topic-2.2.2.1.1-20"></a>

###### Termination: CPAP termination at 1, 2, and 3 years in French national claims

> “Therapy termination was defined as cessation of CPAP reimbursements.”
> “A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male).”
> “Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively.”
> “Therapy termination rates were highest in younger or older patients with ≥1 comorbidity.”

Source: [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/)

<a id="topic-2.2.2.1.1-21"></a>

###### Persistence: five-year PAP persistence under telemonitoring and pay-for-performance in France

> “A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring.”
> “PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years.”
> “Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%).”
> “However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.”

Source: [Baillieul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43033026/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Oral Appliance Therapy

<a id="topic-2.2.2.1.2-1"></a>

###### VA/DoD guideline: mandibular advancement devices or PAP as first-line options for mild to moderate OSA (weak for)

> “18. For treatment of mild to moderate obstructive sleep apnea (Event Index <30 per hour), we suggest either mandibular advancement devices or positive airway pressure as first line therapy options. Weak for”
> “The mandibular advancement device (MAD) is the second most studied therapy for OSA, after PAP therapy.”
> “The remaining evidence base reviewed in 2019 and 2025 supported that while MAD therapy may not be as efficacious in reducing the AHI as PAP therapy, the increased usage of MAD, due in part to patient preference and acceptance, can result in more effective treatment.”
> “While the Patient Focus Group confirmed individual preferences varied, most patients exposed to both options preferred MAD over PAP.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### AASM and AADSM guideline: oral appliances for adults intolerant of CPAP or preferring alternate therapy (standard)

> “We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant of CPAP therapy or prefer alternate therapy. (STANDARD)”
> “When oral appliance therapy is prescribed by a sleep physician for an adult patient with obstructive sleep apnea, we suggest that a qualified dentist use a custom, titratable appliance over non-custom oral devices. (GUIDELINE)”
> “We suggest that sleep physicians conduct follow-up sleep testing to improve or confirm treatment efficacy, rather than conduct follow-up without sleep testing, for patients fitted with oral appliances. (GUIDELINE)”
> “The PubMed database was searched from January 1, 2004, through July 31, 2012, and was updated again on February 28, 2013, to capture the latest literature.”

Source: [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/)

<a id="topic-2.2.2.1.2-3"></a>

###### AASM and AADSM guideline: AHI reduction with oral appliances compared with CPAP, pooled trials, hypopnea scoring rule not stated

> “In weighted analysis, OAs produced a significant mean reduction in AHI, however the mean reduction in AHI was 6.24 events/h (95% CI: 8.14, 4.34) greater with CPAP than with OA.”
> “For patients with moderate to severe OSA, however, the odds of achieving the target AHI were significantly greater with CPAP than with OAs.”
> “A review of the evidence suggests that adherence rates using OAs are greater than those observed with CPAP. However, no randomized controlled trials have assessed objective OA adherence rate as compared with CPAP.”
> “Although they are not as efficacious as PAP therapy, the benefits of using OAs outweigh risks of not using OAs.”

Source: [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/)

<a id="topic-2.2.2.1.2-4"></a>

###### ACP guideline: mandibular advancement devices as an alternative to CPAP (weak recommendation, low-quality evidence)

> “RECOMMENDATION 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence).”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.2-5"></a>

###### ERS guideline: CPAP over mandibular advancement devices, with equivalence in mild to moderate OSA (conditional recommendation, very low quality of evidence)

> “We systematically searched the following databases from 1 January 1946 until 15 June 2020: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE.”
> “In adult patients with OSA, we suggest that CPAP should be used as compared to MAD (conditional recommendation, very low quality of evidence).”
> “Altogether, those considerations lead the panel to regard CPAP and MAD as equal in patients with mild to moderate OSA. With increasing severity of OSA, comorbidities or odontological concerns, CPAP should be considered in this group of patients.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Weight Management and Incretin-based Pharmacotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### VA/DoD guideline: evidence-based weight management combined with other OSA treatment (weak for)

> “20. For treatment of obstructive sleep apnea in patients with overweight or obesity, we suggest evidence-based weight management in combination with other treatments for obstructive sleep apnea. (See VA/DOD CPG on Management of Overweight and Obesity) Weak for”
> “An additional publication was identified that was not included in our literature review because it was published after the cutoff date for this guideline evidence synthesis.”
> “The Work Group is aware that on December 20, 2024, the FDA approved tirzepatide for the treatment of moderate to severe OSA in patients with obesity, to be used in combination with a reduced calorie diet and increased physical activity.”
> “While this study did not impact the strength or direction of the recommendation, additional research on pharmacotherapy for weight loss may further inform this recommendation in the future.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### ATS guideline: comprehensive lifestyle intervention (strong), antiobesity pharmacotherapy evaluation (conditional), and bariatric surgery referral (conditional)

> “We recommend participation in a comprehensive lifestyle intervention program that includes a reduced-calorie diet, exercise/increased physical activity, and behavioral counseling rather than no program (strong recommendation, very low certainty in the estimated effects).”
> “For patients with OSA with a BMI greater than or equal to 27 kg/m2, whose weight has not improved despite participating in a comprehensive weight-loss lifestyle program, and who have no contraindications including no active cardiovascular disease, we suggest an evaluation for antiobesity pharmacotherapy (conditional recommendation, very low certainty in the estimated effects).”
> “For patients with OSA with a BMI greater than or equal to 35 kg/m2, whose weight has not improved despite participating in a comprehensive weight-loss lifestyle intervention program, and who have no contraindications, we suggest referral for bariatric surgery evaluation (conditional recommendation, very low certainty in the estimated effects).”

Source: [Hudgel et al. (2018)](https://academic.oup.com/ajrccm/article/198/6/e70/8498283)

<a id="topic-2.2.2.1.3-3"></a>

###### ATS guideline: literature search dates and pharmacotherapies reviewed

> “Searching was conducted in July and August 2015 and then updated in February 2017 and February 2018.”
> “Our literature search identified three studies of patients with OSA that evaluated the effects of phentermine/topiramate ER (54), liraglutide (55), or orlistat (56).”

Source: [Hudgel et al. (2018)](https://academic.oup.com/ajrccm/article/198/6/e70/8498283)

<a id="topic-2.2.2.1.3-4"></a>

###### ACP guideline: weight loss for all adults with overweight or obesity and OSA (strong recommendation, low-quality evidence)

> “RECOMMENDATION 1: ACP recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight. (Grade: strong recommendation; low-quality evidence)”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.3-5"></a>

###### Tirzepatide label: indication for moderate to severe OSA in adults with obesity

> “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:”
> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### Tirzepatide label: dose escalation and OSA maintenance dosage

> “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
> “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose [see Dosage and Administration (2.2)].”
> “The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”
> “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### Tirzepatide label: design of the OSA trials, AHI of at least 15 and BMI of at least 30

> “The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] ≥15) in patients with obesity (BMI ≥30 kg/m2) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration.”
> “Study 5 enrolled 234 adult patients with moderate to severe OSA and obesity who were unable or unwilling to use Positive Airway Pressure (PAP) therapy.”
> “Study 6 enrolled 235 adult patients with moderate to severe OSA and obesity who were on PAP therapy.”
> “The clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

###### Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation

| Measure | Study 5 placebo (N = 120) | Study 5 ZEPBOUND MTD (N = 114) | Study 5 difference from placebo (95% CI) | Study 6 placebo (N = 114) | Study 6 ZEPBOUND MTD (N = 119) | Study 6 difference from placebo (95% CI) |
| --- | --- | --- | --- | --- | --- | --- |
| AHI change from baseline (events/hr) | “-5.3” | “-25.3” | “-20 (-25.8, -14.2)” | “-5.5” | “-29.3” | “-23.8 (-29.6, -17.9)” |
| Percent change in AHI from baseline | “-3” | “-50.7” | “-47.7 (-65.8, -29.6)” | “-2.5” | “-58.7” | “-56.2 (-73.7, -38.7)” |
| Percent of participants with ≥50% reduction in AHI | “19” | “61.2” | “42.8 (30.8, 54.8)” | “23.3” | “72.4” | “48.6 (36.6, 60.7)” |
| Percent with AHI <5 or AHI 5-14 and ESS ≤10 | “15.9” | “42.2” | “28.7 (18.3, 39.2)” | “14.3” | “50.2” | “33.2 (22.1, 44.3)” |

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

> “Data from polysomnographic studies were scored centrally with the use of the American Academy of Sleep Medicine rule 1B for identification of hypopneas (which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-9"></a>

###### SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”
> “All results are reported with the use of the treatment-regimen estimand unless otherwise specified.”
> “Overall, 82.9% of the participants completed the trial (91.5% in the tirzepatide groups and 74.4% in the placebo groups) and 79.7% adhered to the assigned regimen (87.6% in the tirzepatide groups and 71.9% in the placebo groups) (Fig. S3).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-10"></a>

###### SURMOUNT-OSA: AHI change at week 52, efficacy estimand

> “For the efficacy estimand, the change in AHI at week 52 was −27.4 events per hour (95% CI, −31.6 to −23.2) with tirzepatide and −4.8 events per hour (95% CI, −9.3 to −0.3) with placebo, for an estimated treatment difference of −22.5 events per hour (95% CI, −28.7 to −16.4).”
> “For the efficacy estimand, the change in AHI at week 52 with tirzepatide was −30.4 events per hour (95% CI, −34.3 to −26.5) with tirzepatide and −6.0 events per hour (95% CI, −10.3 to −1.6) with placebo, for an estimated treatment difference of −24.4 events per hour (95% CI, −30.3 to −18.6).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-11"></a>

###### SURMOUNT-OSA: percent change in body weight at week 52, treatment-regimen estimand

| Measure | Trial 1 tirzepatide | Trial 1 placebo | Trial 1 difference | Trial 2 tirzepatide | Trial 2 placebo | Trial 2 difference |
| --- | --- | --- | --- | --- | --- | --- |
| Percent change in body weight (95% CI) | “−17.7 (−19.0 to −16.3)” | “−1.6 (−2.9 to −0.2)” | “−16.1 (−18.0 to −14.2)” | “−19.6 (−21.0 to −18.2)” | “−2.3 (−3.8 to −0.9)” | “−17.3 (−19.3 to −15.3)” |

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-12"></a>

###### AASM provider fact sheet: tirzepatide as part of comprehensive OSA care

> “Consider as part of comprehensive OSA care along with positive airway pressure (PAP) therapy, oral appliance therapy, or surgery as appropriate, not as a replacement for PAP. There is no head-to-head evidence to date that compares Zepbound with other OSA treatments.”
> “Reassess PAP needs as AHI improves along with weight loss; maintain long-term weight plan to sustain OSA benefit.”

Source: [American Academy of Sleep Medicine Zepbound provider fact sheet (2026)](https://aasm.org/wp-content/uploads/2026/04/ProviderFS_Zepbound_2026-DIGITAL-2.pdf)

<a id="topic-2.2.2.1.3-13"></a>

###### AASM guideline: discussion of bariatric surgery referral for adults with BMI of at least 35 who are intolerant or unaccepting of PAP (strong)

> “Recommendation 2: We recommend that clinicians discuss referral to a bariatric surgeon with adults with OSA and obesity (class II/III, BMI ≥ 35) who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).”
> “The TF made a strong recommendation in favor of bariatric surgery referral based on moderate-quality evidence from 2 RCTs and 28 observational studies that showed clinically meaningful improvements in several critical outcomes, and the benefits of discussing referral over the harms of no treatment.”
> “Additionally, iron malabsorption, gastric ulcer, vitamin deficiency, bowel obstruction or leak, gastrointestinal reflux disorder, and gastric band slippage have been reported but the incidence of these is low.”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.3-14"></a>

###### ERS guideline: bariatric surgery evaluation after an unsuccessful weight reduction programme (conditional recommendation, very low quality of evidence), AHI scoring rule not stated

> “In adult obese patients with OSA, we suggest bariatric surgery evaluation versus weight-reducing diet when weight has not improved despite participating in a comprehensive weight reduction programme and if there are no contraindications (conditional recommendation, very low quality of evidence).”
> “The difference between the change scores was −11.5 events·h−1 (95% CI −28.3–5.3 events·h−1), which was not statistically significant (p=0.18).”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Positional Therapy

<a id="topic-2.2.2.1.4-1"></a>

###### VA/DoD guideline: positional therapy for positional OSA (weak for), pooled AHI with hypopnea scoring rule not stated

> “21. For treatment of positional obstructive sleep apnea, we suggest positional therapy. Weak for”
> “Finally, it was associated with an improvement in AHI compared with control (Mean Difference (MD) −7.38 events per hour).”
> “Positional therapy was not associated with improved functional outcomes, overall quality of life (QoL) or sleep-related QoL.”
> “The Work Group’s confidence in the quality of the evidence was very low.”
> “When assessing resource use, positional therapy is a low cost, accessible treatment option.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### ERS guideline: vibratory positional therapy or CPAP in mild or moderate position-dependent OSA (conditional recommendation, very low certainty of evidence), hypopnea scoring rule not stated

> “We suggest either positional therapy using vibratory devices or CPAP among adult patients with mild or moderate position-dependent OSA as defined by a supine AHI at least twice as high as the nonsupine AHI and no relevant nonsupine AHI (<15 events·h−1) (conditional recommendation for either the intervention or CPAP, very low certainty of evidence) (supplementary table e18).”
> “In patients with mild positional OSA, we suggest using either vibrational positional therapy or MAD (conditional recommendation for either the intervention or control, very low certainty of evidence) (supplementary table e19).”
> “However, positional therapy was superior in terms of compliance (CPAP 4.9 h per night, positional therapy +2.5 h per night; 95% CI 1.3–4.6 h per night).”
> “In this context, other studies found the TBT to be associated with low long-term compliance, mostly due to a lack of subjective comfort [85–87].”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.4-3"></a>

###### Cochrane review: positional therapy compared with CPAP and with inactive control, pooled AHI with hypopnea scoring rule not stated

> “We included eight studies. The studies randomised 323 participants into two types of interventions.”
> “Two studies showed that CPAP produced a greater reduction in Apnoea‐Hypopnoea Index (AHI) with a mean difference (MD) of 6.4 events per hour (95% CI 3.00 to 9.79; low‐certainty evidence) compared to positional therapy.”
> “Positional therapy showed a reduction in AHI compared with control (MD −7.38 events per hour, 95% CI −10.06 to −4.7; low‐certainty evidence).”
> “All the studies were of short duration. We are unable to comment on the long‐term effects of the therapies.”

Source: [Srijithesh et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6491901/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Hypoglossal Nerve Stimulation

<a id="topic-2.2.2.1.5-1"></a>

###### VA/DoD 2025 recommendation for referral after unsuccessful positive airway pressure therapy

> “For treatment of obstructive sleep apnea in appropriate* patients (including with an apnea hypopnea index of 15 or greater per hour) who have not been successful with positive airway pressure therapy, we suggest referral for evaluation for hypoglossal nerve stimulation therapy.”
> “Evidence suggests that HGNS improves the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), excessive daytime sleepiness, and health-related quality of life (QoL) in patients with OSA who have not been successfully treated with PAP.”
> “Although our evidence review did not include studies of MAD, clinicians may consider a trial of PAP as well as MAD prior to surgical referral.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### FDA device criteria as summarized in the VA/DoD 2025 guideline

> “HGNS uses an implanted neurostimulator that dilates the upper airway by selectively stimulating branches of the hypoglossal nerve, predominantly innervating the genioglossus muscle, while the device is active during sleep”
> “and a diagnosis of moderate to severe OSA with AHI 15-100 events per hour who have failed or are intolerant to PAP therapy.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Procedure-related and study-related adverse events

> “The published rates of serious adverse events from surgical implantation and device use are low (196), although one RCT (n=138 patients) reported that 72.5% of patients experienced a total of 164 procedure or study-related adverse events.(195)”
> “The most common non-serious procedure-related adverse events were wound healing (e.g., erythema, seroma; 15.2% patients), temporary incisional numbness (13.8% patients), and post-op discomfort related to incisions (12.3% patients), and the most common non-serious study-related adverse event was discomfort due to stimulation (33% of patients).(195)”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### ERS 2021 recommendation: salvage treatment rather than first-line treatment

> “We suggest that HNS should not be used as first-line treatment for OSA patients in general (conditional recommendation, very low quality of evidence). However, we suggest that HNS compared to no treatment should be considered as a salvage treatment in patients with symptomatic OSA, who cannot be sufficiently treated with positive airway pressure treatment (CPAP, bilevel positive airway pressure) or MAD, and who have an AHI <50 events·h−1 and a BMI <32 kg·m−2 (conditional recommendation, very low quality of evidence) (supplementary table e13).”
> “There is limited evidence available for this intervention; a general recommendation was based on selected patients from three RCTs with very strict patient selection (only ∼10% of the screened patients were included) [20, 52, 53].”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.5-5"></a>

###### STAR trial: eligibility and twelve-month outcomes, AHI scored by a core laboratory with standard criteria

> “Participants with moderate-to-severe obstructive sleep apnea were eligible for enrollment if they had difficulty accepting or adhering to CPAP treatment.”
> “The primary outcome measures were assessed by means of overnight polysomnography and scored by an independent core laboratory with the use of standard criteria.”
> “The median AHI score decreased 68%, from the baseline value of 29.3 events per hour to 9.0 events per hour. The median ODI score decreased 70%, from 25.4 events per hour to 7.4 events per hour.”
> “At the 12-month visit, the criteria for the coprimary outcome of a reduction of at least 50% in the AHI score from baseline and an AHI score of less than 20 events per hour were met by 66% of the participants (83 of 126 participants; lower boundary of the 97.5% confidence interval [CI], 57).”
> “The rate of procedure-related serious adverse events was less than 2%.”

Source: [Strollo et al. (2014)](https://www.nejm.org/doi/full/10.1056/NEJMoa1308659)

<a id="topic-2.2.2.1.5-6"></a>

###### STAR trial: five-year outcomes

> “From a cohort of 126 patients, 97 completed protocol, and 71 consented to a voluntary polysomnogram.”
> “AHI response rate (AHI <20 events per hour and >50% reduction) was 75% (n = 71). When a last observation carried forward analysis was applied, the responder rate was 63% at 5 years. Serious device-related events all related to lead/device adjustments were reported in 6% of patients.”

Source: [Woodson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29582703/)

<a id="topic-2.2.2.1.5-7"></a>

###### Manufacturer description of hypoglossal nerve stimulation as an alternative

> “A surgically implanted hypoglossal nerve stimulator can be an option for some patients with moderate to severe OSA who fail PAP.”
> “Additionally, only approximately 100,000 patients have received this treatment over the lifetime of its availability as of March 2025.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Upper Airway and Maxillomandibular Surgery

<a id="topic-2.2.2.1.6-1"></a>

###### AASM 2021 recommendations on referral for surgical consultation

> “We recommend that clinicians discuss referral to a sleep surgeon with adults with OSA and BMI < 40 kg/m2 who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).”
> “We suggest that clinicians discuss referral to a sleep surgeon with adults with OSA, BMI < 40 kg/m2, and persistent inadequate PAP adherence due to pressure-related side effects as part of a patient-oriented discussion of adjunctive or alternative treatment options (CONDITIONAL).”
> “We suggest that clinicians recommend PAP as initial therapy for adults with OSA and a major upper airway anatomic abnormality prior to consideration of referral for upper airway surgery (CONDITIONAL).”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.6-2"></a>

###### Evidence base, benefits, and harms of upper airway surgery as rescue therapy

> “The TF made a strong recommendation in favor of discussing surgical referral based on a large body of low-quality evidence from 4 randomized controlled trials (RCTs) and 239 observational studies showing clinically meaningful and beneficial differences in nearly all critical outcomes, and the benefits of discussing referral over the harms of no treatment.”
> “Meta-analyses demonstrated a clinically significant reduction in excessive sleepiness, snoring, BP, and AHI/RDI, and a clinically significant improvement in sleep-related and general QOL.”
> “Additionally, potential persistent long-term side effects have been reported including dysphagia, taste alteration, mandibular paresthesia, perceived worsening of facial appearance, aspiration, hemorrhage, and globus pharyngeus, but the incidence of these is low.”
> “A potential limitation regarding this management option is access to a surgeon familiar with the variety of modern surgical techniques for OSA.”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.6-3"></a>

###### Maxillomandibular osteotomy compared with CPAP in the ERS 2021 guideline

> “50 adults with OSA were randomised to maxillo-mandibular osteotomy (MMO) or auto-adjusting positive airway pressure (auto-adjusting CPAP).”
> “1 year after the intervention, AHI decreased by 48.7 events·h−1 (from 56.8±16.5 events·h−1 to 8.1±7.0 events·h−1), while in the control group it decreased by 44.0 events·h−1 (from 50.3±12.4 events·h−1 to 6.3±1.9 events·h−1). The difference between the score changes was not statistically significant (p=0.21).”
> “In adult patients with OSA, the task force suggests using either MMO or CPAP (conditional recommendation, very low quality of evidence) (supplementary table e16).”
> “Moderate adverse effects were associated with MMO, which could also require additional orthodontic work.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.6-4"></a>

###### VA/DoD 2025 recommendation on nasal surgery to support positive airway pressure use

> “For treatment of obstructive sleep apnea in patients with anatomical nasal obstruction as a barrier to positive airway pressure use, we suggest evaluation for nasal surgery.”
> “A systematic review (SR) conducted by Camacho et al. (2015) demonstrated that after sinonasal surgery to improve nasal breathing, the proportion of patients regularly using PAP increased from 39% to 90%(221).”
> “Furthermore, access to a qualified surgeon could be a limiting factor for some patients, especially in rural or remote areas.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.6-5"></a>

###### Manufacturer description of surgical options

> “Patients who reject or do not tolerate PAP may be treated with a variety of surgical procedures that generally are designed to reduce anatomic obstruction by surgically removing tissue in the upper airway. Only a small segment of OSA patients are candidates for these procedures, and success rates are variable.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Wakefulness-promoting Agents for Residual Sleepiness

<a id="topic-2.2.2.1.7-1"></a>

###### VA/DoD 2025 recommendation for armodafinil, modafinil, or solriamfetol

> “For treatment of obstructive sleep apnea-related residual excessive daytime sleepiness in patients who are optimally treated with sufficient therapy use, we suggest adding:”
> “Moderate quality evidence suggests that both modafinil and armodafinil improve the critical outcomes of sleepiness and quality of life (QoL).(224)”
> “Moderate quality evidence suggests that solriamfetol improves sleepiness.(224) High-quality evidence suggests that solriamfetol improves QoL.(226)”
> “considerations include caution against prescribing armodafinil, modafinil, or pitolisant in patients with cardiovascular disease.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.7-2"></a>

###### Confirming adherence and efficacy of airway treatment before adding a wake-promoting agent

> “Therefore, treating providers should confirm that patients are using their treatment for OSA during the entire sleep period before considering addition of a wake-promoting agent.”
> “Insufficient sleep is very common in the general population and must be ruled out as a cause of EDS prior to prescribing wake-promoting agents.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### Solriamfetol label: indication and limitation of use in OSA

> “SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA)”
> “SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness.”

Source: [Axsome Sunosi prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Armodafinil label: indication and limitation of use in OSA

> “NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).”
> “In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.”

Source: [Teva Nuvigil prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Wake-promoting agents outside the scope of the ERS 2021 guideline

> “In addition, several drugs address the problem of residual sleepiness despite optimal treatment of the underlying disease [103–105]. Unfortunately, these findings could not be included in this project as they do not focus on the causal treatment of the disease itself and major studies were published after the time limit of the literature searches.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Limitations of Current Therapies

<a id="topic-2.2.2.1.8-1"></a>

###### Summary

- PAP nonadherence, by definition: with adherence defined as more than 4 hours of nightly use, 46% to 83% of people with OSA have been reported to be nonadherent (Weaver and Grunstein 2008). Relative to a 7-hour night, the overall CPAP non-adherence rate across 20 years of studies was 34.1%, with no significant improvement over that period (Rotenberg et al. 2016). By the CMS definition (at least 4 hours of use on 70% of nights in a consecutive 30-day period within the first 90 days), the observed 90-day adherence rate was 75% (Cistulli et al. 2019), which also cites prior studies in which up to 24% of patients may not fulfill their PAP prescription. The VA/DoD 2025 guideline states that as many as half of patients prescribed PAP have been unable to adopt it long-term. Mean adherence in the CPAP groups of two cardiovascular outcome trials was 3.3 hours per night (McEvoy et al. 2016) and 2.78 hours per night (Sánchez-de-la-Torre et al. 2020).
- PAP termination and persistence: in claims data, with termination defined as cessation of CPAP reimbursements, termination rates among 480,000 people were 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years (Pépin et al. 2021); a second analysis of 174,270 individuals reported a 1-year termination rate of 22.3% (Bailly et al. 2024). Under telemonitoring (95.7% of 84,550 people), PAP persistence was 83.5% at 1 year, 68.4% at 3 years, and 60.5% at 5 years, and issues with PAP treatment accounted for 54.9% of documented reasons for stopping (Baillieul et al. 2026).
- Cardiovascular outcomes: CPAP did not reduce cardiovascular events in randomized trials. In one trial (McEvoy et al. 2016), a primary end-point event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group after a mean 3.7 years (hazard ratio 1.10; 95% CI 0.91 to 1.32). Cardiovascular events occurred in 16% vs 17% in a second trial (Sánchez-de-la-Torre et al. 2020; hazard ratio 0.89; 95% CI 0.68 to 1.17), and the primary endpoint in 18.1% vs 22.1% in a third (Peker et al. 2016; hazard ratio 0.80; 95% CI 0.46 to 1.41). A meta-analysis of 10 randomized trials (7266 participants) found a relative risk of 0.77 (95% CI 0.53 to 1.13) for a composite of acute coronary syndrome, stroke, or vascular death. An individual participant data meta-analysis (4186 participants) found a hazard ratio of 1.01 (95% CI 0.87 to 1.17) for the first major adverse cardiac or cerebrovascular event, and 0.69 (95% CI 0.52 to 0.92) with good adherence in an on-treatment analysis. The AASM guideline finds insufficient and inconclusive evidence to recommend or withhold PAP in non-sleepy adults to reduce cardiovascular events or mortality.
- Oral appliances: in pooled trials (hypopnea scoring rule not stated), the mean AHI reduction was 6.24 events/h greater with CPAP than with oral appliances, and the odds of reaching the target AHI in moderate to severe OSA were greater with CPAP; no randomized trial has compared objective oral appliance adherence with CPAP (AASM and AADSM guideline). The ERS guideline suggests CPAP over mandibular advancement devices (conditional recommendation, very low quality of evidence) and regards the two as equal in mild to moderate OSA.
- Positional therapy: guideline recommendations apply to positional OSA (VA/DoD, weak for) and to mild or moderate position-dependent OSA with a nonsupine AHI below 15 events/h (ERS). In a review of 8 studies (323 participants; hypopnea scoring rule not stated), CPAP reduced the AHI by 6.4 events per hour more than positional therapy (2 studies), all studies were of short duration, and long-term effects could not be assessed. The VA/DoD guideline states that positional therapy was not associated with improved functional outcomes or quality of life, with very low confidence in the evidence.
- Hypoglossal nerve stimulation: the FDA device criteria summarized by the VA/DoD guideline include moderate to severe OSA with an AHI of 15 to 100 events per hour and failure of or intolerance to PAP. The ERS guideline suggests against its use as first-line treatment and suggests it as salvage treatment for patients with an AHI below 50 events/h and a BMI below 32 kg/m2; its trials included about 10% of screened patients. In one randomized trial cited by the VA/DoD guideline, 72.5% of 138 participants experienced a total of 164 procedure- or study-related adverse events. Apnimed cites invasiveness, cost, and BMI and airway collapse pattern exclusions, and states that approximately 100,000 patients had received the therapy as of March 2025.
- Tirzepatide: its OSA indication is limited to moderate to severe OSA in adults with obesity, with a reduced-calorie diet and increased physical activity; its OSA trials enrolled adults with an AHI of at least 15 and a BMI of at least 30 kg/m2. The AASM fact sheet states that there is no head-to-head evidence comparing it with other OSA treatments.
- Wake-promoting agents: the solriamfetol and armodafinil labels indicate them to improve wakefulness in OSA and state that neither treats the underlying airway obstruction.

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/); [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/); [Cistulli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6589354/); [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf); [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599); [Sánchez-de-la-Torre et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31839558/); [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/); [Bailly et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039934/); [Baillieul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43033026/); [Peker et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26914592/); [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/); [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/); [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/); [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/); [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/); [Srijithesh et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6491901/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf); [American Academy of Sleep Medicine Zepbound provider fact sheet (2026)](https://aasm.org/wp-content/uploads/2026/04/ProviderFS_Zepbound_2026-DIGITAL-2.pdf); [Axsome Sunosi prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf); [Teva Nuvigil prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf)

<a id="topic-2.2.2.1.8-2"></a>

###### Positive airway pressure nonadherence across studies

> “When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to treatment.”

Source: [Weaver and Grunstein (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2645251/)

> “The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.1.8-3"></a>

###### Long-term adoption of positive airway pressure in the VA/DoD 2025 guideline

> “As many as half of patients prescribed positive airway pressure (PAP) therapy for the treatment of OSA have been unable to adopt PAP therapy long-term.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.8-4"></a>

###### Cardiovascular outcomes with positive airway pressure: SAVE trial

> “In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.”
> “Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.2.1.8-5"></a>

###### Cardiovascular outcomes with positive airway pressure: meta-analysis of randomized trials

> “In this meta-analysis of 10 randomized clinical trials including 7266 patients, there was no significant association of PAP compared with no treatment (or sham PAP) on a composite outcome of acute coronary syndrome events, stroke, or vascular death (relative risk, 0.77 [95% CI, 0.53-1.13]). There was also no significant association with individual outcomes or all-cause death.”

Source: [Yu et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5541330/)

<a id="topic-2.2.2.1.8-6"></a>

###### Insufficient evidence for positive airway pressure to reduce cardiovascular events in non-sleepy adults

> “There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.1.8-7"></a>

###### Eligibility limits of hypoglossal nerve stimulation and surgery

> “The invasiveness of both the diagnostic testing and implantation procedure, the high cost of the procedure, and exclusions of patients with BMI above a certain threshold or with an upper airway collapse pattern that are not amenable to treatment with the device, can be a deterrent to”
> “These procedures are invasive and painful and can have complications such as nerve damage or swallowing difficulties.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-8"></a>

###### Wake-promoting agents do not treat airway obstruction

> “These drugs can help OSA patients stay more awake during the day but do not treat the underlying disease or alleviate night-time breathing disruption and hypoxemia that is linked to cardiovascular risk.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-9"></a>

###### No pharmacotherapy approved for OSA without obesity before tirzepatide, manufacturer statement

> “Prescription drug development in the field of OSA is relatively novel, and until the approval of tirzepatide in 2024 for moderate to severe OSA in obese adults in combination with a reduced-calorie diet and increased physical activity, the FDA historically did not have well-established therapeutic endpoints for this indication.”
> “While weight loss treatments have broad appeal, they are not clinically relevant for the majority of OSA patients, as most lack a distinct approval in OSA and tirzepatide’s approved indication is limited to only those individuals with moderate-severe OSA and a comorbid diagnosis of obesity.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.1.8-10"></a>

###### Limited applicability of current alternatives in an editorial on SynAIRgy

> “Alternative interventions, such as oral appliances, hypoglossal nerve stimulation, and weight loss strategies, including pharmacologic approaches such as tirzepatide in selected patients with obesity, have expanded the range of available therapies. However, these approaches are not universally applicable, and many patients remain untreated or inadequately treated.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

- Guideline sequencing: the VA/DoD 2025 algorithm prescribes PAP as first-line therapy for severe OSA (AHI above 30 events per hour) and PAP or a mandibular advancement device for an AHI of 5 to below 30, and refers patients who do not adopt or use PAP or a mandibular advancement device to a sleep medicine specialist. The ACP recommends CPAP as initial therapy (strong recommendation, moderate-quality evidence) and mandibular advancement devices as an alternative (weak recommendation, low-quality evidence). The AASM and AADSM recommend that sleep physicians consider oral appliances for adults intolerant of CPAP therapy or preferring alternate therapy. After PAP is unsuccessful or not accepted, guidelines suggest referral for hypoglossal nerve stimulation evaluation when the AHI is 15 or more per hour (VA/DoD) and recommend discussing referral to a sleep surgeon when the BMI is below 40 kg/m2 or to a bariatric surgeon when the BMI is 35 kg/m2 or more (AASM). Wake-promoting agents are suggested for residual excessive daytime sleepiness in patients optimally treated with sufficient therapy use (VA/DoD).
- VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin for OSA (“Weak against”). It rests on 2 randomized trials with mixed results, low confidence in the evidence, and known harms (atomoxetine may increase blood pressure; oxybutynin's anticholinergic effects can increase the risk of falls and cause cognitive impairment). The guideline notes that aroxybutynin is not approved by the FDA. Its evidence review ended on March 31, 2024, and it states that randomized trials of these agents as salvage or adjunctive therapy are needed; Apnimed states that both AD109 phase 3 trials, SynAIRgy and LunAIRo, were completed in 2025.
- AD109 phase 3 population: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP. PAP failure was defined as no PAP use for at least 3 months before randomization or return or removal of the device, and PAP refusal as refusal of PAP after a positive sleep study or refusal of a recommended sleep study due to unwillingness to consider PAP. In the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal.
- Apnimed's stated positioning: the initial launch would focus on the approximately 10.5 million people in the United States diagnosed with OSA but untreated (from a 2025 National Sleep Foundation survey), then on patients using another treatment whose OSA is not fully resolved (as a complement to PAP or GLP-1 therapies), with first-line use as the long-term target. The company presentation describes the target patient as intolerant to PAP (refused or failed), diagnosed within the past 2 years, and without insomnia or active cardiovascular disease. Apnimed plans 125 to 150 field representatives covering 15,000 to 20,000 sleep specialists and high-volume primary care practices. Company-cited surveys report that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it (Wells Fargo, August 2025) and that approximately 80% of 1,500 surveyed patients reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA (SHINE Survey).
- An editorial on SynAIRgy describes AD109 as a likely addition to a multimodal treatment framework, particularly for patients unable or unwilling to use PAP.

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf); [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/); [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/); [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/); [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/); [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/); [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177); [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.2-2"></a>

###### VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin

> “For treatment of obstructive sleep apnea, we suggest against atomoxetine or a combination of atomoxetine and oxybutynin. (Weak against | Reviewed, New-added)”
> “Evidence from 2 RCTs (203,204) provided mixed results on whether atomoxetine or the combination of atomoxetine and oxybutynin improve critical outcomes of obstructive sleep apnea (OSA) such as reductions in apnea hypopnea index (AHI), improvements in daytime functioning, or sleep-related quality of life (QoL).”
> “The combination of atomoxetine and aroxybutynin showed a reduction in AHI, daytime fatigue, and respiratory arousal. Aroxybutynin, the R-enantiomer of oxybutynin, is not approved by the FDA and not commercially available.”
> “Confidence in the quality of overall evidence was rated as low due to small sample sizes and the risk for imprecision. A weak against recommendation for atomoxetine and the combination of atomoxetine and oxybutynin was made because of known harms from these medications, inconclusive evidence that they are effective in OSA, and the low quality of evidence.”
> “Specifically, atomoxetine may increase blood pressure and exacerbate cardiovascular disorders and oxybutynin’s anticholinergic effects can increase risk for falls and cause cognitive impairment.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-3"></a>

###### VA/DoD 2025 guideline: evidence review period and research need, predating AD109 phase 3 results

> “Based on evidence reviewed through March 31, 2024”
> “Randomized control trials (RCTs) or SRs of RCTs published on or after May 15, 2018, to March 31, 2024.”
> “RCTs of atomoxetine and combination of atomoxetine and oxybutynin as a salvage or adjunctive therapy for OSA are needed.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-4"></a>

###### VA/DoD 2025 treatment sequence and referral to a sleep medicine specialist

> “Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour)”
> “Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”
> “Refer patients for follow up to a sleep medicine specialist:”
> “Who do not adopt/use PAP and/or MAD therapy”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-5"></a>

###### Manufacturer positioning: launch focus, then adjunctive and first-line use

> “We intend to focus our initial launch phase of Oxnimbi, if approved, on the approximately 10.5 million people in the United States who are diagnosed with OSA but untreated, estimated based on the results of a survey conducted by the National Sleep Foundation in 2025”
> “Thereafter, we intend to focus on patients using another treatment who have not fully resolved their OSA, for example, providing Oxnimbi as a compliment to PAP or GLP-1s. Our long-term target market is patients seeking initial treatment, with Oxnimbi as a first-line solution, and analogs suggest that oral therapies are likely to evolve into first-line treatments over time.”
> “Given its direct and distinct mechanism, we believe Oxnimbi, if approved, could be used as a potential complement to PAP and GLP-1 therapies in obese patients with moderate-to-severe OSA, in addition to serving the full spectrum of OSA patients, including those who are not obese.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-6"></a>

###### Manufacturer description of the target patient

> “We believe that the target patient is readily identifiable, aligns with clinical intuition, and can offer the highest probability of treatment success and positive feedback”
> “Intolerant to PAP (refused or failed)”
> “Unencumbered absence of insomnia, and active CV disease”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.2.2.2-7"></a>

###### Manufacturer-cited surveys of anticipated prescribing and patient demand

> “A Wells Fargo survey conducted in August of 2025 reported that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it, if approved, either as a first-line therapy, after PAP or together with PAP”
> “Market research conducted by us reported that surveyed healthcare providers believe Oxnimbi, based on its product profile description, could help reengage approximately 50% of their diagnosed but untreated patients.”
> “The SHINE Survey indicated that of the 1,500 patients surveyed, approximately 80% reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA, defined as an AHI reduction of 50%.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-8"></a>

###### Care setting: sleep specialists and primary care, manufacturer statement

> “The legacy, PAP machine-dominant, OSA treatment paradigm has been concentrated primarily in sleep specialists.”
> “We expect to deploy a targeted field sales organization of 125 to 150 representatives focused initially on covering 15,000 to 20,000 sleep specialists and high-volume primary care practices that manage patients with OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-9"></a>

###### Place in a multimodal treatment framework in an editorial on SynAIRgy

> “AD109 may not replace established therapies such as PAP, but it more likely represents a useful addition to a multimodal treatment framework, particularly for patients who are unable or unwilling to use PAP therapy.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Distribution of pathophysiologic traits in OSA

> “One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.”

Source: [Eckert et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3826282/)

<a id="topic-2.2.2.3-2"></a>

###### Endotypic predictors of complete response to atomoxetine plus oxybutynin, AHI with 3% desaturation or arousal hypopnea rule

> “Hypopneas were defined as a reduction in flow ≥ 30% from baseline, lasting at least 10 s, and associated with an arousal from sleep or an oxyhemoglobin desaturation ≥ 3%.”
> “Figure 5 shows individual data: eight of 14 subjects had a complete response to ato-oxy (50% reduction in AHI from placebo and AHI on drug < 10 events/h). These data show that patients with an AHI on placebo < 40 events/h, Fhypopneas > 65%, and Vpassive > 55% were associated with the best likelihood of complete response on ato-oxy.”
> “Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.”

Source: [Taranto-Montemurro et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7268440/)

<a id="topic-2.2.2.3-3"></a>

###### MARIPOSA post hoc subgroups, AHI with 4% desaturation hypopnea rule

> “Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement). However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.2.2.3-4"></a>

###### SynAIRgy prespecified subgroups by sex, severity, and BMI, AHI with 4% desaturation hypopnea rule

> “Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3). AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.2.2.3-5"></a>

###### Pooled phase 3 analysis: subgroups by baseline severity under both estimands and by BMI under the on-treatment estimand, AHI with 4% desaturation hypopnea rule

> “An analysis of sub-groups based on baseline OSA severity showed similar clinical response in participants with mild, moderate, and severe OSA at baseline (Figure 20). In each subgroup and for both estimands, more participants achieved AHI reductions at each threshold with AD109 compared to placebo (Figure 21).”
> “A similar analysis was conducted using sub-groups based on baseline BMI, including those without obesity (BMI<30), those with mild obesity (BMI 30-35), and those with more severe obesity (BMI>35). As shown in Figure 22, more participants achieved AHI reductions at each threshold with AD109 compared to placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.3-6"></a>

###### Pooled phase 3 analysis: patient-reported outcomes by baseline sleepiness, treatment policy and on-treatment estimands

> “Moreover, in a prespecified subgroup of participants with ESS ≥ 10, representing patients with greater baseline sleepiness (approximately two standard deviations above the mean general population value of about six), AD109 demonstrated a statistically significant improvement in PROMIS Fatigue and PROMIS Sleep Impairment compared with placebo in both the treatment-policy (p<0.05) and on-treatment (p<0.01) estimands.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.3-7"></a>

###### Variability in response and symptomatic benefit confined to subgroups in an editorial on SynAIRgy

> “However, among participants with greater baseline symptom burden of fatigue and sleepiness, improvements in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue scores were observed, suggesting that symptomatic benefit may be confined to selected subgroups.”
> “In addition, variability in treatment response highlights the need for strategies to identify patients most likely to benefit.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.3-8"></a>

###### Atomoxetine plus oxybutynin in Japanese participants: responders within a null trial

> “The values of AHI, nadir SpO2 , 3% oxygen desaturation index (ODI), 4% ODI, and SpO2 drop time of <90% did not significantly differ between patients receiving ATO-OXY administration and no medication.”
> “However, the subanalysis demonstrated an obvious decrease in AHI in five responder patients.”
> “Future studies for identifying treatment response group characteristics are warranted.”

Source: [Kinouchi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36184258/)

<a id="topic-2.2.2.3-9"></a>

###### Atomoxetine plus oxybutynin for 30 days in predominantly severe OSA, AHI with 3% and 4% desaturation hypopnea rules

> “Thirty-nine people with predominantly severe OSA received 80/5 mg ato-oxy, 40/5 mg ato-oxy, 40/2.5 mg ato-oxy, or placebo nightly for 30 days in a double-blind, randomized, parallel design.”
> “Apnea-hypopnea index (AHI) with 4% oxygen desaturation and hypoxic burden decreased by ∼50% with 80/5 mg ato-oxy from baseline but not versus placebo (e.g., AHI with 3% oxygen desaturation and AHI with 4% oxygen desaturation difference at Night 30 was -8.2 [95% confidence interval, -22.5 to 6.2] and -8.5 [95% confidence interval, -18.3 to 1.3] events/h, respectively).”

Source: [Aishah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36538809/)

<a id="topic-2.2.2.3-10"></a>

###### Adherence as a modifier of cardiovascular benefit with positive airway pressure

> “The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).”

Source: [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/)

Additional sources: [Messineo et al. (2023)](https://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2023.PA3594); [Gell et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41932835/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### AASM 2019 recommendations for educational, behavioral, troubleshooting, and telemonitoring interventions

> “We recommend that educational interventions be given with initiation of PAP therapy in adults with OSA. (STRONG)”
> “We suggest that behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”
> “We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)”
> “The TF identified 18 RCTs that evaluated the use of some combination of an educational, behavioral, or troubleshooting intervention as an adjunct to initiation of PAP therapy compared to PAP therapy with usual care. Meta-analyses demonstrated a clinically significant improvement in PAP adherence with all three types of interventions.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.4-2"></a>

###### VA/DoD 2025 recommendation for in-person or telehealth adherence interventions

> “For treatment of obstructive sleep apnea in patients who are prescribed positive airway pressure therapy, we suggest the use of in-person or telehealth educational, behavioral, and supportive interventions to improve PAP usage. (Weak for | Reviewed, New-replaced)”
> “Behavioral interventions showed the most significance in hourly usage with an increase in average PAP usage per night by 1.31 hours per night (95% CI: 0.95 to 1.66) when compared to usual care.”
> “In a meta-analysis from Niu et al. (2023)(217) telemedicine-based follow-up significantly improved PAP use greater than 4 hours a night by 10.67% (95% CI: 4.97 to 16.37; p<0.001)”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-3"></a>

###### VA/DoD 2025 recommendation for a short course of eszopiclone to improve positive airway pressure usage

> “For treatment of obstructive sleep apnea in appropriate patients, we suggest up to a two-week course of eszopiclone to improve positive airway pressure usage. (Weak for | Reviewed, New-added)”
> “The systematic review (SR) by Wang et al. (2021)(220) included six randomized controlled trials (RCTs) and two retrospective cohort studies, finding that eszopiclone significantly improved PAP usage compared to placebo or no treatment (Mean Difference: 0.83 hours/night; 95% CI: 0.70 to 0.96; P<0.00001).”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-4"></a>

###### Behavioral intervention effect on CPAP use across studies

> “Behavioral intervention improved adherence rates by ~1 h per night on average.”

Source: [Rotenberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4992257/)

<a id="topic-2.2.2.4-5"></a>

###### Multidisciplinary follow-up of hypoglossal nerve stimulation

> “Patients who use HGNS therapy require periodic evaluation to assess their nightly use of the device, the effectiveness of the therapy for improving their OSA symptoms, and adverse effects of therapy.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.4-6"></a>

###### Manufacturer plans for telehealth pathways and durable medical equipment provider engagement

> “If Oxnimbi is approved, we plan to engage where possible with DME organizations to help identify patients who are unable to initiate or sustain PAP therapy and who may require further clinical evaluation by their healthcare providers.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Positive airway pressure: sleepiness, sleep-related quality of life, and blood pressure

> “Meta-analyses demonstrated a clinically significant improvement in sleepiness with the use of PAP to treat adults with OSA as compared with no treatment. The overall quality of evidence, based on the critical outcome of sleepiness, was high.”
> “Meta-analyses of sleep-related QOL, as assessed by the Calgary Sleep Apnea QOL Index (SAQLI) and the Functional Outcomes of Sleep Questionnaire (FOSQ), demonstrated a clinically significant improvement. However, meta-analyses of global QOL, as assessed by the SF-36 component scores, demonstrated no clinically significant improvement.”
> “Meta-analyses demonstrated clinically significant BP reductions in nocturnal, daytime, and 24-hour systolic and diastolic BP when all patients in the studies were considered, with the largest effects seen for nocturnal measurements.”

Source: [Patil et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374094/)

<a id="topic-2.2.2.7-2"></a>

###### Positive airway pressure: motor vehicle crash risk

> “A meta-analysis of 9 observational studies examining crash risk of drivers with OSA pre- vs. post-CPAP found a significant risk reduction following treatment (risk ratio = 0.278, 95% CI: 0.22 to 0.35; P < 0.001).”

Source: [Tregear et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2941424/)

<a id="topic-2.2.2.7-3"></a>

###### Treatment targets for residual AHI in the VA/DoD 2025 guideline

> “For PAP therapy, this includes an automated interrogation of the device to ensure that the residual AHI is less than 5 events/hr.”
> “For patients with very severe OSA, it may not be feasible to reduce the AHI to less than 5 and in these cases, consultation with a sleep specialist is recommended.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.7-4"></a>

###### Effectiveness accounting for adherence: mean disease alleviation

> “Mean disease alleviation is a metric that incorporates adherence and efficacy to estimate real-world effectiveness [11]. Therefore, comparisons among treatments should be based on effectiveness rather than efficacy alone.”
> “Given the low adherence rates associated with PAP, a treatment that reduces the AHI to below 10 events/h, or even to a higher residual AHI, could achieve effectiveness similar to that of PAP with a residual AHI below 5 events/h if adherence is substantially better.”

Source: [Kim (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434379/)

> “Studies should incorporate mean disease alleviation, a metric that incorporates both treatment efficacy and hours of therapy use as outcomes.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Outcome metrics beyond AHI

> “Development of this Research Statement was motivated by a growing recognition of the limitations of the AHI to predict adverse effects of OSA and to predict responsiveness to treatment.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-2.2.2.7-6"></a>

###### AD109: magnitude of AHI change and categorical outcomes in SynAIRgy, AHI with 4% desaturation hypopnea rule, treatment policy estimand

> “Among 646 participants (median apnea-hypopnea index [AHI], 19.6), treatment with AD109 over 26 weeks resulted in a placebo-adjusted reduction in AHI of approximately 4 events per hour. The clinical significance of this magnitude of reduction is uncertain when considered as a continuous measure.”
> “However, categorical analyses provide additional context: 41.8% of participants receiving AD109, as compared with 33.6% receiving placebo, had a decrease in AHI sufficient to shift to a lower severity category, and 17.6% achieved an AHI of less than 5 events per hour, compared with 9.3% in the placebo group.”
> “Whether pharmacologic reductions in hypoxic burden translate into improved clinical outcomes remains uncertain, but the observed changes are consistent with a biologically plausible mechanism of benefit.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.7-7"></a>

###### AD109: baseline severity and absolute effect size, authors' interpretation of SynAIRgy

> “The population studied skewed toward mild-to-moderate baseline disease severity, which can contribute to limited absolute effects despite meaningful proportional improvements.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.2.2.7-8"></a>

###### AD109: outcomes not yet established

> “The durability of the observed physiologic effects beyond 26 weeks (with results forthcoming from the 51-week LUNAIRO trial), the long-term safety profile of combined noradrenergic and antimuscarinic therapy, and the impact on clinically meaningful outcomes, including cardiovascular events, require further study.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
